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ABSTRACT 
 
EPIGENETIC REGULATION OF CANCER-TESTIS GENE EXPRESSION 
 
Aydan Bulut 
M.S. in Molecular Biology and Genetics 
Supervisor: Dr. Ali O. Güre 
August 2008, 108 Pages 
 
Cancer-testis (CT) genes are composed of mostly X-linked gene families that are 
widely expressed in cancer, in a coordinate manner, with ideally no expression in 
normal tissues except spermatogonia, oogonia and trophoblasts. Exact 
mechanisms reactivating their expression during carcinogenesis are not known 
yet. Epigenetic factors emerge as key controllers of CT expression. Selective DNA 
demethylation of the promoter regions of CT genes has been demonstrated to 
correlate closely with CT expression in all examples studied so far. Tumor-
suppressor genes (TSGs), on the other hand, are known to be frequently down-
regulated in cancer by hypermethylation of DNA. In order to elucidate 
mechanisms that could help explain tumor-specific CT gene up-regulation, we 
aimed to understand how these seemingly opposite effects could exist in close 
proximity. For this purpose, we identified eight CT-proximal X-linked putative TSGs 
(pTSGs) down-regulated in tumors, by screening the SAGE and EST libraries of the 
Cancer Genome Anatomy Project. By conventional and real-time RT-PCR, we 
verified that two such genes, ALAS2 and CDR1, were significantly down-regulated 
in almost all cancers tested, while three others were down-regulated at least in 
some cancers, and by bisulfite sequencing we demonstrated that the promoter 
DNA of these pTSGs were hyper-methylated in correlation with their expression 
levels.  
Our search for the presence of insulators between CT and TSG genes did not yield 
a consensus site. However, we hypothesized that the dynamic organization of CT 
genes into inverted repeats (identified by the Inverted Repeats Finder program) 
throughout the X chromosome could be a candidate regulator of CT expression. By 
using the chromosome conformation capture (3C) assay, we have shown the 
alteration in higher-order chromosomal structure of the CT gene NY-ESO-1-
bearing inverted repeat region in SK-LC-17 as well as in 5-Aza-2’-deoxycytidine-
treated HT29 cell lines, correlating with CT as well as ncRNA expression from 
within the repeat. As it is known that many CT genes are embedded in inverted 
repeats, our results suggest a general mechanism regarding epigenetic regulation 
of CT gene expression.   
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ÖZET 
 
KANSER-TESTİS GEN İFADESİNİN EPİGENETİK DENETLENMESİ 
 
Aydan Bulut 
Moleküler Biyoloji ve Genetik Yüksek Lisansı 
Tez Yöneticisi: Dr. Ali O. Güre 
Ağustos 2008, 108 Sayfa 
 
Kanser-testis (KT) genleri, çoğunlukla X kromozomu üzerinde yer alan, normal 
dokular içerisinde ideal olarak sadece spermatogonia, oogonia ve trofoblastta ve 
fakat birçok kanser türünde de, koordine olarak, ifade edilen gen ailelerinden 
oluşurlar. Hangi mekanizmaların kanserde tekrar çalışmalarına yol açtığı büyük ilgi 
odağı olduğu halde halen tam olarak bilinmemektedir. Epigenetik etmenler bu 
bağlamda ana denetleyiciler olarak ortaya çıkmaktadır. Promotor bölgesi seçici 
DNA demetilasyonunun KT ifadesiyle sıkıca bağlantılı olduğu çalışılan tüm 
örneklerde gösterilmiştir. Diğer yandan, tümör baskılayıcı genlerin (TBG) ise 
DNA’nın aşırı-metillenmesi sonucu kanserlerde ifade azalmasına uğradıkları 
bilinmektedir. Kanser-testis genlerinin tümör-özgün ifade artışına yol açan 
mekanizmaları izah edebilmek amacıyla, öncelikle bu iki ters işleyişin birbirine 
yakın olarak nasıl var olabildiğini anlamaya çalıştık. Bu amaçla Kanser Genomu 
Anatomi Projesi’nin SAGE ve EST kütüphanelerini tarayarak sekiz adet KT-komşusu 
X-bağlantılı varsayımsal tümör baskılayıcı gen belirledik. Geleneksel ve gerçek 
zamanlı PZR ile bu tarz iki genin, ALAS2 ve CDR1’in, ifadelerinin test edilen hemen 
bütün kanserlerde önemli ölçüde azaldığını ve başka üç genin ifadelerinin ise en az 
birkaç kanser türünde azaldığını tespit ettik. Bisülfit dizileme tekniğini kullanarak, 
bu varsayımsal TBGlerin promotor DNAlarının aşırı-metillenmesinin, genlerin ifade 
düzeyleriyle orantılı olduğunu da gösterdik. 
KT ve TBG genleri arasında yalıtkan elemanların olup olmadığını araştırdık, bu 
çalışmanın sonucunda konsensus bir yalıtım bölgesi olmadığını belirledik. Ne var ki, 
KT genlerinin X kromozomu boyunca, tersine tekrarlı DNA bölgeleri içinde yer 
almasını; kromozom yapısının KT ifadesi üzerinde denetleyici olabileceği olasılığı 
olarak önerdik. Biyokimyasal 3C yöntemini uygulayarak, NY-ESO-1 içeren tekrarlı 
DNA bölgesinin kromozom yapısının SK-LC-17 ve 5-Aza-2’-deoksisitidin ile 
muamele edilmiş HT29 hücre hatlarında değiştiğini gösterdik. Bu değişim aynı 
zamanda protein kodlamayan-RNA ve KT ifade seviyelerinin değişimiyle 
bağdaşıktır. Birçok KT geninin tersine tekrarlı DNA bölgeleri içerisinde yer aldığı 
bilindiğinden dolayı, sonuçlarımız genel bir KT epigenetik denetleme 
mekanizmasını ileri sürmektedir.  
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1 INTRODUCTION 
1.1  Cancer-Testis (CT) Genes and Antigens 
Cancer-testis antigens constitute a group of mostly X-linked testicular antigens, 
the familial and immunogenic properties of which were realized by mid-90’s, and 
new members were identified rapidly since then.  CTs are immunogenic and have 
vaccination potential because they are widely expressed in cancers with no 
expression in normal tissues except testis; and cytotoxic T cells can recognize the 
CT antigens. The initial discovery of the first CT-antigens MAGEA1, BAGE and 
GAGE1 between 1991-95 was through T cell epitope cloning, thus they were found 
as cytotoxic T lymphocyte-recognized antigens [1-3]. SSX2 and NY-ESO-1 were 
discovered after 1995 by another technique, SEREX (serological expression 
cloning), developed by Pfreundschuh et al [4-7]. From then on, the application of 
SEREX technique led to identification of many additional CT-antigens, the number 
of which was further increased by high-throughput transcript analyses [8, 9]. 
Today 82 CT gene families with 263 genes can be found in literature [10]; although 
only a subgroup have testis-restricted expression and are immunogenic. An up-to-
date list of CT genes is given in Appendix A. 
Individual CT antigens proposed to be used as tumor biomarkers are MAGE A1/A3 
for hepatocellular carcinoma and lung adenocarcinoma, BORIS for breast cancer, 
NY-ESO-1 for lung adenocarcinoma, etc [11-13]. However, CT antigens are more 
likely to be candidate biomarkers when assessed in combination since their 
expression is thought to be triggered by the same mechanism [11]. In addition, 
some CT antigens bear the potential to be used for early diagnosis of cancer, 
demonstrated by few studies [13, 14].   
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1.1.1  Structure 
Cancer-testis genes can be divided into two groups according to chromosomal 
location. Most CTs are on the X chromosome and are referred to as CT-X genes 
[15]. Members of CT-X group exist mostly as multi-copy gene families, some also 
containing splice variants. They reside in tandem or inverted repeats and consist 
approximately 10% of the genes on the X chromosome. Duplications of the 
unstable repeat regions are thought to be the primary mechanism increasing CT 
copy number on chromosome X [10].  
CT genes located on autosomal chromosomes are mostly single-copy genes that 
are not associated with segmental duplications (yet).   
Regarding the similarity of the CT genes, different families have slight homology 
with each other (e.g. NY-ESO-1 and LAGE1, CAGE-HAGE and XAGE-GAGE-PAGE 
homologies) while members of the same family generally have sequence similarity 
of >90% [16].  
The best-studied of all CT genes is the MAGE superfamily. Individual families 
within the MAGE superfamily are related to each other, such that they all have the 
MHD (MAGE homology domain) that encodes a ~200 residue stretch of conserved 
protein domain [17, 18]. The rest of MAGE proteins are nearly completely 
different in each family. According to sequence analysis, the MAGE superfamily 
involves 3 acidic groups, MAGE A, B and C; and a basic group, MAGE D [19].  
None of other CTs but CAGE gene bearing a DEAD box exhibit structural domains, 
in correlation with their limited functionality and evolutionary history [20]. These 
aspects are reviewed in sections 1.1.2 and 1.1.3.  
 
1.1.2  Function 
Many of the CT antigens do not have characterized biological functions. Early-
identified major CT families fall into this group with the major exception being the 
MAGE superfamily. Some MAGE orthologs have defined functions. Mouse MAGE 
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B4 plays role in germ cell development; mouse necdin binds to E2F1 and 
negatively regulates G1 to S progression [19]. In a similar fashion, Drosophila 
necdin controls neural precursor proliferation in postembryonic neurogenesis [21]. 
Similarly MAGE A4 binds to the Gankyrin or p28 protein and inhibits the adhesion-
independent growth of Gankyrin-overexpressed cells [19]. Recently MAGE-A3/6 
was identified as a novel target of fibroblast growth factor 2-IIIb (FGFR2-IIIb) 
signaling in thyroid cancer cells, such that FGF7/FGFR2-IIIb activation resulted in 
H3 methylation and deacetylation of the MAGE-A3/6 promoter, to down-regulate 
gene expression [22]. 
Within those CTs that are known to have a function, a subgroup consists of 
meiosis-related proteins, like SCP1 (CT8) which is a synaptonemal complex protein 
involved in chromosome reduction in meiosis, and OY-TES-1, which encodes the 
proacrosin binding protein sp32 precursor [16]. Both SCP1 and OY-TES-1 are non-X 
CT antigens.   
Within other functional CT genes are BORIS and CAGE. BORIS (brother of the 
regulator of imprinted sites) is the paralog of the abundant transcription factor 
CTCF, and seems to play role in CT-regulation according to the studies showing 
BORIS and CTCF binding to NY-ESO-1 and MAGE A1 promoters, resulting in 
derepression of both antigens [23-25]. CAGE, on the other hand, is a DEAD box 
helicase protein, expression of which is sensitive to the cell cycle. CAGE was thus 
suggested to play a proliferative role [20]. SSX antigen is still a candidate to be 
placed among functional CTs with a possible role in stem-cell migration and cancer 
cell metastasis, since it overlaps in cytoplasm with matrix metalloproteinase 2 
(MMP2) and its down-regulation impairs cell migration with a reduction in MMP2 
levels [26].  
An interesting finding that may shed light to the functionality of CTs was published 
in 2006, declaring the first direct physical interaction between two CT antigens, 
the homology domain of MAGE C1 and NY-ESO-1 [27]. Although it is not yet 
known whether this interaction is associated with the function of either of the two 
antigens, or rather an artifact resulting from putatively same CT-regulatory 
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mechanism (like a non-functional weak interaction resulting from the abundance 
of CT antigens within the cell in cases of coordinate hypomethylation); yet it would 
be beneficial to examine the possible interactions between other CT antigens.   
 
1.1.3  Conservation 
CT genes are almost exclusively specific to primates, with few exceptions. Few 
members of the MAGE superfamily are found in mouse genome, the mostly 
conversed one being necdin because of its functionality. Indeed, MAGE genes have 
expanded in both rodent and primate lineages, but independently [17]. In general, 
human CT genes have orthologs in primates, especially in great apes. CT genes in 
the chimpanzee genome are highly similar to human orthologs and generally 
located on the same chromosomes [10]. Members of the GAGE family are 
tandemly arranged on the X chromosome only in human, chimpanzee and 
macaque genomes. Phylogenetic analyses reveal that the GAGE family began to 
duplicate after the split of human and chimpanzee [28].  
As a recent estimate of the future evolution of CT genes, the divergence rate 
between human and chimpanzee CT orthologs was analyzed, which shows that CT-
X genes are evolving faster than non-X CT genes [10]. 
The absence of CT genes in genomes of model organisms is a challenge for CT 
research, since generation of knock-out strains and other manipulations are 
limited. Only the necdin knock-out was generated in mouse [19]. As a result, CT 
research is based on patient samples and germ cells.   
 
1.1.4  Expression (and Acting Epigenetic Mechanisms)   
Most cancer-testis genes are expressed in none of the normal adult tissues but 
testis, and then, only at the spermatogonial stage. However, recent research 
suggest they may be among genes escaping MSCI (meiotic sex chromosome 
inactivation) thus being expressed in spermatids also [29]. Based on their 
expression profiles in a panel of normal tissues, CT genes are classified as testis-
5 
 
restricted (1), tissue-restricted (expressed in ≤2 of 13 non-gametogenic tissues 
tested) (2), differentially expressed (expressed in 3-6 non-gametogenic tissues, 
among 13 tested) (3) and ubiquitously expressed (4) [30]. The initially-discovered, 
major CT gene families fall in the testis- and tissue-restricted groups. Some genes 
referred to as ‘CT’ are thus controversially classified if the testis-specific 
expression rule is strictly applied. CT genes are also expressed, in a coordinate 
manner, in a wide-variety of cancers including lung cancer (especially non small-
cell lung cancer), hepatocellular carcinoma, cancers of prostate, ovary, esophagus, 
hematological malignancies, multiple myeloma, head and neck squamous 
carcinoma, lymphoma, multiple myeloma, colorectal and gastric cancers and 
Hodgkin’s sarcoma; and are generally correlated with poor prognosis [11, 16]. 
What reactivates their expression during carcinogenesis is of great interest, 
however the exact mechanisms are not known yet. Genetic mutations are not 
responsible for this task, since these genes are expressed in germline with no 
known mutation. Although some CT family members are frequently involved in 
translocations, like SSX2 within t(X:18) region [4, 31], this seems to be the 
exception rather than the rule. Epigenetic factors therefore emerge as key 
controllers of CT expression. DNA demethylation associated with CT gene 
expression is the most frequently reported mechanism shown for many cancer 
types [12, 32]. Expectedly, treatment with the DNMT inhibitor, 5-AZA-2’-
deoxycytidine, induces CT gene expression [33]. ‘Genome-wide hypomethylation’ 
is a phenomenon believed to associate or possibly cause CT gene expression; 
however promoter-dependent selective demethylation (restricted to the 5’ 
region) was shown to be the case for MAGE-A1 [34]. Histone modifications, 
namely (de-)acetylation, are known to affect CT expression, shown both in vivo 
and pharmaceutically by trichostatin A (HDAC inhibitor) treatment [32]. 
Acetylation-induced transcription was shown to be required for DNA 
demethylation of CTs, at least for the GAGE family; and since CT genes are 
coordinately expressed, this may be part of the real mechanism resulting in gene 
expression [35].  
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Since CT-X genes are organized in repeated regions on the X chromosome, we 
hypothesized that at some point before or after histone acetylation the higher-
order chromosomal structure (and may be the nuclear localization) should alter 
leading to formation of permissive structures for CT gene expression. We further 
hypothesized that this could resulting in, or happen as a consequence of the 
generation of non-coding transcripts. Transcription factors known to have a role in 
CT expression, like Sp1, CTCF, BORIS, and others, should also have a role within 
this scenery before initiation of transcription. Adequate understanding of the CT-
activation mechanisms is required for therapeutic purposes, since inhibition of CT-
derepression might help us proceed in our combat with cancer and other complex 
diseases.    
 
1.2  Epigenetic Regulation of Transcription  
Whatever exceeds beyond the borders of genetics falls in the fields of epigenetics 
and RNA biology. Investigation of epigenetic statuses and mechanisms assisted us 
understand how cell fates are different, how the zygote is not just a product of the 
egg and sperm, why identical twins raised together are not really identical? 
General knowledge regarding epigenetic mechanisms, namely, DNA methylation, 
histone modifications, and chromatin remodeling, are summarize in the following 
sections; how these mechanisms are altered in cancer, germ, and stem cells is also 
summarized. 
 
1.2.1  Methylation/Demethylation of DNA 
In mammals, methylation of DNA appears almost exclusively in the form of 
cytosine methylation (on the 5’ end) of CpG dinucleotides. Other types of DNA 
methylation include CNG and CNN residues. Although not studied as widely as CpG 
methylation, recent research suggests that non-CpG methylation might play 
important roles in the mammalian epigenome as well [36]. DNA methylation 
exerts its effect by suppressing transcription and is an indispensible process for 
mammalian development, and the post-developmental maintenance of the 
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healthy state. Genomic imprinting, X chromosome inactivation, gene- and tissue-
specific expression are some basic phenomena that directly include CpG 
methylation. Bearing in mind that 50 - 70% of all human genes contain CpG islands 
might clarify the abundant role of DNA methytransferases. Methylation statuses 
are very dynamic, yet heritable upon cell division enabling long-term memory of 
transcriptional levels [36, 37].  
Three enzymes act as CpG methyltransferases in mammals: Dnmt1, Dnmt3a and 
Dnmt3b [38, 39]. Dnmt1 is the maintenance methyltransferase which acts on 
hemi-methylated DNA during replication and is essential for X inactivation and 
imprinting [40]. Dnmt3a and Dnmt3b are de novo methyltransferases playing both 
collaborative and unique roles mostly in development [41]. Dnmts also act as co-
repressors in protein complexes. 
How reversal of DNA methylation is achieved is a controversial issue. In the classic 
‘replication-coupled demethylation’ point of view, DNA methylation is reduced 
progressively upon each replication [42]. Inhibition of Dnmt1 activity by 
nucleoprotein complexes or histone modifications associated with transcription 
(e.g. acetylation) is required [42]. A more novel aspect is the existence of active 
DNA demethylases, either removing the methyl group from the cytosine residue, 
or removing the 5’-methylcytosine itself by glycosylase activity which requires 
endonuclease activity afterwards for repairing the missing base [42]. The former 
pathway is mediated by a protein that belongs to the family of MBD (methyl CpG-
binding domain) proteins in vitro but it is not yet isolated in vivo [42]. 
Direct analysis of DNA methylation is possible through sodium bisulfite treatment 
followed by sequencing or restriction digestion (COBRA assay: COmbined Bisulfite 
Restriction Analysis) [43]. Alternatively, methylation-sensitive restriction 
endonucleases may be employed and afterwards the product is amplified by PCR 
reaction. One drawback of restriction-mediated assays is their limitedness to 
restriction sites. Genome-wide maps of methylation states can be generated 
through microarray hybridization or high-throughput sequencing of bisulfite 
treated DNA samples. Lastly, treating cells with 5-AZA-2’-deoxycytidine, a cytosine 
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analog which cannot be methylated, and investigation of transcript levels would 
provide an indirect analysis of DNA methylation [44].  
1.2.2  Histone Modifications 
Human DNA of approximately 2m length is large enough to exceed the borders of 
a cell nucleus, which is the major reason why higher-order chromatin structures 
exist. Nucleosome is the basic structural unit that consists of four core histones – 
H2A, H2B, H3 and H4 – around which 147 bp DNA is wrapped. Linker histone H1 is 
employed between two nucleosomes and brings them closer to generate a more 
compact structure named the ‘30nm fiber’. Further compactness is enabled by 
wrapping this fiber further utilizing protein scaffolds, finally generating 
chromosomes. The core histones play additional roles other than being a scaffold 
for wrapping DNA: the N-terminal and C-terminal tails bear more than 60 residues 
that can be covalently modified. Known histone modifications include lysine 
acetylation, lysine and arginine methylation, serine and threonine 
phosphorylation, lysine ubiquitination, lysine sumoylation and proline 
isomerization [45]. Methylation is more complex than other modifications since 
there are mono-, di- and trimethyl states for lysines and mono- and dimethyl 
(asymmetric and symmetric) for arginine [45]. The enormous number of 
combinations that the histone modifications might exist in, dectates a ‘histone 
code’ that regulates accessibility of DNA in first hand [46].  
The putative ’histone code’ implies specific and heritable combination of histone 
modifications for specific functional roles. This has 3 consequences; firstly, 
organization of DNA into global chromatin environments - euchromatin and 
heterochromatin - that generates the banding pattern of chromosomes. The 
borders of chromosome bands have shown to be separated by boundary elements 
flanked by methylated H3K4 and H3K9 [47]. Heterochromatic states of the inactive 
X chromosome and pericentric heterochromatin are maintained by recruitment of 
specific proteins to methylated H3K27 and H3K9, respectively. Second 
consequence is the short-term regulation of biological processes like transcription, 
replication and repair through recruitment of chromatin remodeling complexes. 
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Although which combinations of modifications directly imply activation or 
repression is not still clear, H3K4me1, 2 and 3, H3K27me1, H3K9me1, H3K79me1, 
H4K20me1 and all acetylations are generally associated with transcription 
whereas H3K9me3, K3K27me3 and H3K79me3 are generally connected to 
transcriptional repression [47, 48]. A third effect is the long-term memory of 
transcriptional state, which plays putative roles in development and 
differentiation [46].  
Almost each of the histone modifications are exerted by different enzymes. In 
general, histone acetyltransferases (HATs) and deacetylases (HDACs) carry out (de-
)acetylation; histone methyltransferases (HMTs) - specifically lysine and arginine 
methyltransferases- and lysine demethylases carry out (de-)methylation; and 
serine/threonine kinases carry out phosphorylation. No arginine demethylases 
have been identified to date [45]. An up-do-date list of histone-modifying enzymes 
is given in Appendix B. 
Apart from the core histones and the linker histone H1, there are other histone 
proteins named ‘histone variants’, which are employed in more specific processes. 
Such histone-variant genes have introns and are often polyadenylated unlike 
major histone RNAs. H2A and H3 variants are the widely studied ones. H2A.X plays 
role in maintaining genome integrity, it acts in double-strand break DNA repair, 
apoptosis, [V(D)J] recombination and replication [49]. H2A.Z was shown to be 
indispensible for survival however its exact role is yet to be determined. There are 
controversial data suggesting a role for H2A.Z in both transcriptional activation 
and repression, but it is certainly enriched in boundary elements between 
euchromatic and heterochromatic regions [50]. Another H2A variant, macroH2A, 
is thought to be involved in transcriptional repression and replaces H2A on the 
inactive X chromosome. The histone H3 variant H3.3 varies from H3 by only 4 
amino acids, however it carries out remarkably different functions. It is enriched in 
some tissues during development. It is associated with actively transcribed regions 
of the genome, replacing H3 during transcriptional elongation, and constitutively 
expressed during the cell cycle accordingly. CENP-A, another H3 variant, is also 
essential for survival and localizes to centromeric heterochromatin [49]. Apart 
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from these, there are also testis-specific histone variants that may even play role 
in cancer-testis gene expression. Three models - replication-coupled histone 
deposition, transcription-coupled histone deposition and histone exchange (by 
certain factors) - have been proposed to explain how variant histones incorporate 
into the chromatin, though none has been proven [50].   
Histone modifications are usually analyzed by chromatin immunoprecipitation 
(ChIP) using antibodies specifically recognizing modified residues. The generation 
of histone maps of human, mouse and yeast have been successfully performed by 
high throughput assays based on hybridizing ChIP samples on arrays (ChIP on chip) 
or by massively parallel signature sequencing of ChIP samples (ChIP-Seq) [47, 48]. 
Alternatively, histone modifications might be analyzed using mass spectrometry.   
 
1.2.3  Polycomb/Trithorax Group Proteins and Chromatin Remodeling 
Transcriptional regulation through modifications of DNA and histones discussed 
above seem to be the final steps in the regulation of a gene. To understand which 
mechanisms precede histone and DNA modifications, one needs to take into 
account polycomb group (PcG) and trithorax group (trxG) protein complexes, and 
other chromatin remodeling complexes. For the reasons explained below, these 
complexes are candidate major players determining the active/suppressed states 
of transcription, higher order chromosomal architecture, and even non-coding 
RNA transcripts.  
PcG and trxG proteins were firstly discovered in D.melanogaster as activators or 
repressors, respectively, of Homeobox (Hox) genes, which define cell identity 
along the anteroposterior axis. In this context, they are required to maintain the 
state of expression, not to initiate or cease. Most of the involved proteins have 
defined human orthologs, that regulate Hox genes as well as many others. PcG 
and trxG proteins play role in some basic phenomena like genomic imprinting, X 
inactivation, pluripotency and cell proliferation [51].  
Polycomb repressor complexes (PRC) are divided into two groups based on their 
physical association in different multiprotein complexes. Class II PRCs are directly 
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involved in repression of transcription while class I PRCs are methyltransferase 
complexes that maintain the repressed state [52]. PRC2 is a class I PRC that has 
four core components: E(z), Esc, Su(z)12 and Nurf-55 (these are the Drosophila 
proteins). Enhancer of Zeste (E(z)) is a the SET1- domain containing histone 
methyltransferase that trimethylates H3K27 and H1K26, the former of which is 
recognized by the chromodomain of Polycomb (Pc), which Is a core component of 
PRC1 complex (class II inhibitory complex). PRC1 has four core components in 
stoichiometric amounts: Pc, Polyhomeotic (Ph), Posterior sex combs (Psc) and and 
dRING. A recently identified third PcG complex is PhoRC, which includes sequence-
specific DNA binding protein Pho. The mechanism of PRC action at target sites is 
rather sophisticated and not fully understood yet. PcG proteins are recruited to 
target genes’ polycomb response elements (PREs) via sequence-specific DNA-
binding factors and/or by specific histone modifications (namely, H3K27me3). 
PREs are often several kilobases long and contain recognition sites for some 
protein motifs; however, they are proposed to have a bifunctional nature since 
trxG proteins also bind to trithorax response elements (TREs) overlapping PREs 
[51]. PcG recruitment might even involve components of the RNAi machinery, 
since recent data showed that while siRNA-mediated silencing of a gene promoter, 
AGO1 recruited EZH2 (human homolog of Drosophila E(z)) [53]. Most probably, 
binding of PcG and trxG complexes at target sequences is mediated by 
combinatorial signals from DNA and histone motifs, and requires other DNA-
binding factors.  
Once recruited, PRC complexes might suppress transcription via direct or indirect 
mechanisms. Direct inhibition of the transcriptional machinery is a choice, and 
supporting this notion, TAFIIs are stoichiometric components of PRC1. Generation 
of repressive chromatin environments by heterochromatinization is the indirect 
method, which is supported by in vitro data showing that PRC1 complex bound to 
chromatin does not allow remodeling by Swi/Snf complex as it does not allow 
transcription by RNA polymerase II [54, 55]. Long-range interactions of DNA and 
PcG complexes are putative further steps of regulation, either in the form of 
looping or PcG polymerization. These interactions might be required because of 
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large distances between PREs and promoters of target genes. In vitro, 
recombinant PcG complexes of Drosophila and mammals bound to an immobilized 
chromatin template can silence a second free chromatin in trans [56]. On the 
other hand, many PcG proteins can oligomerize or self-associate, which may be an 
important functional property for silencing [52].  
Trithorax activatory complexes are divided into five groups: The ATP-dependent 
chromatin remodelers SWI/SNF and NURF (a member of the ISWI family), and SET-
domain factors TAC1, Ash1 and MLL1-3 [51]. TrxG-mediated activation is less 
wellcharacterized than PcG-mediated silencing. Like PcG recruitment, trxG 
recruitment involves DNA and histone motifs (TREs and H3K4me3) and non-coding 
RNA. According to a recent study, non-coding transcripts from the bxd regulatory 
region of the Drosophila Ubx gene recruit the Ash1 protein to this region, inducing 
activation [57]. Current models of trxG-mediated activation suggest that the SET-
domain factors induce H3K4 trimethylation which is recognized by ATP-dependent 
chromatin remodelers [51]. Remodeling of chromatin either by exchange of 
nucleosomal subunits, by sliding the nucleosomes, or by looping out of 
nucleosomal DNA provides permissive environment for transcription [58].  
Apart from PcG and trxG proteins, there are other chromatin-modifier complexes 
that regulate transcription. Among these are the ATP-dependent chromatin 
remodelers similar to SNF: NuRD/Mi-2/CHD and INO80 families [58]. Such as the 
bromodomain of SWI/SNF proteins recognizing acetylated histone tails, NuRD/Mi-
2/CHD family members have unique tandem chromodomains that recognize 
methylated histone tails. INO80 family members, on the other hand, are 
characterized by split ATPase domains. All ATP-dependent chromatin remodelers 
are highly conserved from yeast to human, indicating their essential functions in 
variety of cellular processes. They have both shared and unique roles. All are 
capable of both inducing and repressing transcription, depending on the local 
chromatin context.  Unique processes involve roles of ISWI family members in 
chromatin assembly after DNA replication, SWI/SNF and INO80 family members in 
double strand-break repair, and NuRD/Mi-2/CHD members in maintenance of 
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pluripotency in ES cells [58]. Deregulation of these essential complexes therefore 
contributes to uncontrolled cell growth and complex diseases.    
 
1.3  Epigenetics of Germ- and Stem-Cells 
Stem cells and germ cells bear completely different epigenetic regulation of the 
genome when compared with somatic cells, which also are significantly different 
from each other. This is reasonable, since differentiation genes are switched off in 
these cells; gene expression should be adjusted to maintain the dedifferentiated 
state. How these choices are made and the mechanisms involved are of great 
interest both because the differentiation phenomenon is not completely 
understood yet and because of the therapeutic potential of stem-cell research. 
Recent knowledge regarding stem- and germ-cell epigenetics is therefore 
presented here.  
There are two main classes of stem cells: embryonic and adult (or somatic) stem 
cells. Embryonic stem cells (ESCs) are pluripotent (‘plural potency’), meaning that 
they can give rise to the three different cell lineages; ecto-, meso- and endo-derm, 
but not to extra-embryonic tissues. ESCs are established from the totipotent 
blastomeres within the inner cell mass of blastocyst. The zygote and early 
blastomeres are totipotent (‘total potency’), they can give rise to the whole 
organism. The difference between totipotent and pluripotent states is vastly an 
issue of epigenetics. Zygotic division is termed cleavage and regulated by maternal 
factors that exist within the egg that contribute to zygotic transcription also. 
Among the maternal factors are pluripotency factors like Sox2 and Oct3/4 and 
many chromatin-modifying enzymes like PcG proteins, histone-modifiers and 
chromatin remodelers that help reactivate the quiescent genome. The zygote is 
thus intrinsically regulated and does not have self-renewal capacity. ESCs, on the 
other hand, operate their own expression, are responsive to external signals and 
are capable of self-renewal. Pluripotency only exists transiently in a developing 
embryo, until the gastrulation stage. The exception is the germ-cell lineage that 
expresses pluripotency factors after gastrulation [59, 60].  
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How pluripotency is maintained is a highly debatable issue; however transcription 
of pluripotency factors were shown to be a pre-requisite. ChIP-Chip experiments 
show that in human ES cells, 3 major factors, OCT3/4, SOX2 and NANOG, together 
bind to the promoter regions of 2260 genes, 1303 of which are actively 
transcribed and 959 of which are inactive genes, creating a complex gene network 
that can be regulated by these factors [59]. However, the criteria for choice of 
some genes instead of others and the resulting epigenetic modifications that lead 
to maintenance of pluripotent state have not been adequately delineated. 
Bivalent chromatin marks, meaning the chromosomal regions that carry both 
repressive and permissive histone modifications in adult tissues, are considered 
signs of pluripotency-related genes however this hypothesis has not been proved 
yet [47, 61]. 
 Adult stem cells emerge when ESCs somehow differentiate and lose pluripotency 
so that they now can give rise to cells of a specific lineage. Different types of adult 
stem cells, mainly mesenchymal and hematopoietic, have self-renewal capacity 
but are restricted in differentiation, thus they are multi-potent [61]. Adult stem 
cells are found in minute amounts in bone marrow and stem-cell niches specific to 
some organs. Umbilical cord blood is a rich source of hematopoietic stem cell 
isolation [62].      
Germ cells are the only cells that express pluripotency factors after gastrulation, as 
mentioned above. Since germ cells , when fused, are expected to give rise to a 
totipotent zygote at the end of their developmental program, their specialization 
includes repression of somatic differentiation followed by extensive erasure of the 
epigenetic modifications - like DNA and H3K9 methylation - in order to reprogram 
the whole genome. As a result, pluripotency factors like Sox2, Nanog, Stella and 
Nanos3 are reactivated. Although germ cells cannot give rise to diverse cell types, 
pluripotent cells can be obtained from them in vitro [60].  
All cells within the body of an individual are differentiated under one specific 
lineage, except from germ cells and adult stem cells. Epigenetic mechanisms rule 
repression of inappropriate developmental programs temporally and spatially, 
15 
 
while maintaining heritability of current phenotypic states. The maintenance of 
cell fate is highly fulfilled by PcG and TrxG proteins. Strikingly, the nucleus of a 
differentiated somatic cell that has lost cellular potency can be reprogrammed by 
the maternal factors in the cytoplasm of an unfertilized egg, but also by ES and EG 
cells [59].  
Expression of cancer-testis genes in germ cells, especially in testis, results from the 
differentially regulated epigenome of these cells. Germ cells and dedifferentiated 
cancer cells, or ‘cancer stem cells’, absolutely share some of the epigenetic 
mechanisms and pluripotency factors, that make them both express CT genes; 
however these factors are yet to be fully discovered and characterized.   
 
1.4  Epigenetics of Cancer 
Cancer is a complex disease that needs to combine many aberrant operations 
within the cell to emerge. A cancer cell acquires more and more capabilities as it 
accumulates genetic mutations and misregulation in non-mutated genes. Genetic 
and epigenetic aberrations cooperate within the pre-cancerous cell to make it 
acquire six capabilities as ‘hallmarks’ of cancer, meaning general to most cancers, 
as listed by Hanahan and Weinberg: Self-sufficiency in growth signals, insensitivity 
to anti-growth signals, evading apoptosis, limitness replicative potential, sustained 
angiogenesis, tissue invasion and metastasis [63]. The order of these events varies 
among different cancer types [63]. But the main questions are to understand the 
reason why and how a healthy cell quits the established intracellular and 
extracellular regulatory circuits and turns to uncontrolled cell growth. Cancer 
research yielded sound improvements in answering these questions, which are 
concerned by thousands of people all over the world. Tumor suppressor genes and 
oncogenes were discovered as a result of cancer research, as genes inactivated 
and promoted in cancer, namely cancer genes [64, 65]. They sure have roles in 
prognosis of cancer because there is an established idea that each cancer gene 
brings an advantage to the cancer cell in terms of gaining the capabilities 
mentioned above [64, 65]. The cellular pathways abused by cancer cells are well-
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characterized, however the causes or effects of these events on the whole 
genome are still not exactly known.  
Although Hanahan and Weinberg did not mention about epigenetics as an 
important acting mechanism in carcinogenesis, we today know that epigenetic 
aberrations are as destructive as genetic ones in the route to uncontrolled cell 
growth [66]. In fact, regarding these two phenomena as two different incidents 
would be a big mistake since they are closely linked to each other. For example, 
candidate genetic alterations affecting genes involved in the great epigenetic 
machinery, like DNMTs, histone acetylases and deacetylases, and the SWI/SNF 
chromatin remodeling complex were proposed to be causes of epigenetic 
aberrations that are in turn exerted by these proteins within cancer cells [67]. The 
epigenetic aberrations shown to contribute tumorigenesis include changes in DNA 
methylation, histone modifications, chromatin remodeling, and regulation of small 
RNAs [67-72]. Involvement of chromosomal higher-order structure and non-coding 
transcripts are newly being studied [73-75]. In other words, every aspect of 
epigenetic systems is affected from the carcinogenesis process and they also exert 
broad range of changes to many sites of the genome. Another scenario of cancer 
progression attributes a much more major role to epigenetic factors. In this 
scenario, polyclonal epigenetic disruption of cancer stem cells leads to 
accumulation of later genetic and epigenetic aberrations which are required for 
tumor progression [76].  
Among the above mentioned epigenetic alterations in cancer, aberrant DNA 
methylation is the most detailedly studied of all; thus will be the main focus of this 
section. Both aberrant hypo-methylation and hyper-methylation take place, 
examplified by misregulation of cancer-testis genes and tumor suppressor genes, 
respectively [68, 77] . Since hyper-methylation of TSGs have more direct affect on 
cellular proliferation as boosting cell growth [78], many researchers are trying to 
understand which TSGs are aberrantly methylated and at what stage of 
carcinogenesis these events take place. The first TSG promoter shown to be hyper-
methylated in a human cancer belongs to the Retinoblastoma gene, and was 
discovered in 1989 [79]. However, hypermethylation of CpG islands being a 
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common mechanism of TSG inactivation in cancer was widely accepted when 
p16INK4a was also shown to be inactivated by hypermethylation in 1995 [80-82]. 
After this discovery, many researchers focused on searching new tumor 
suppressor genes that are epigenetically inactivated and succeeded in finding 
BRCA1, RASSF1, estrogen, androgen, progesterone and retinoic acid receptors in 
this class as striking examples [83-87]. On the other side, many key TSGs are 
proved to be normally methylated, like BRCA2, PTEN and p19INK4d [88-91]. Today, 
100-400 CpG islands are estimated to be hyper-methylated in a given tumor [92] 
and many key cellular pathways suffer from inactivation of the TSGs, like the p53 
network, cell cycle, DNA repair, apoptosis, hormone and vitamin response, etc. 
[93].  
CpG hypermethylation of TSGs are rather specific to different types of tumors, 
both in sporadic tumors and in familial-inherited cancers, where it acts as a 
‘second hit’ [94]. The ‘methylotype’ of a given tumor is the term used for the 
complete profile of CpG island methylation throughout the genome. The 
methylotype data for various tumors, although limited to known CpG islands, 
indicate that tumors of gastrointestinal origin (esophagus, colon, stomach) are 
significantly more methylated than others like ovarian tumors [92].  Exposure to 
external carcinogens within this tract is the most possible answer [67]. The 
methylotype data points methylation hot spots on human chromosomes 3p, 1p35 
and 11p15 where multiple genes are hyper-methylated, thus the region behaves 
like a large loss of heterozygosity locus [67, 95-97].  
CpG island hypermethylation is common to many types of cancer and seems to 
have a deep impact in cancer progression. In order to proceed in answering the 
key questions regarding hyper-methylated TSGs and all other components 
affected from aberrant DNA methylation (miRNAs, DNA repeats, oncogenes, CT 
genes etc.), the necessity to plot a human epigenome map arouse. The Human 
Epigenome Project aims to produce the tissue-specific DNA methylation profiles of 
the human genome and is thus under construction [98]. The Human Epigenome 
Pilot Project is completed and first data of the main project came from human 
chromosomes 6, 20 and 22 [98]. Once finished, the results will profoundly 
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enhance our understanding of both the targets of epigenetic machinery and the 
operation criteria of this machinery as well.   
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2 MATERIALS & METHODS 
Cell Lines and Culturing 
HCC cell lines HCT15 and Colo205 were grown in RPMI media (HyClone 
#SH30027.01); HCT116 and LoVo were grown in DMEM (HyClone #SH30307) for 
bisulfite sequencing analysis. All media were supplemented with 10 % FBS 
(HyClone #SH30160.03), 1% peniclllin/streptomycin (HyClone #SV30010), 1 % L-
glutamine (HyClone #SH3004.01) and 1 % non-essential amino acids (HyClone 
#SH30238.1). Media were changed every three days; cells were split while 
exponentially growing. DNA from above cell lines plus Ls174T and Lim1215 was 
used for PCR detection.  
DNA and RNA extraction 
DNA from appropriate cell-lines for bisulfite sequencing experiments was 
extracted with UltraCleanTissue DNA Isolation Kit (MoBio #12334). Peripheral 
blood lymphocyte DNA was extracted from whole blood with hypotonic swelling 
method.  RNA was extracted from all cells by Tri-reagent (MRC #TR 118). DNase I 
treatment (DNA-Free Kit, Ambion #AM1906) was performed after extracting the 
RNA.  
2.1 Expression Analyses of Putative TSGs 
Selection of Putative Tumor Supressor Genes on X chromosome 
X-chromosome genes that are downregulated, with respect to their normal 
counterparts, in any human cancerous tissue except from embryonic and germline 
origin were identified by analyzing SAGE Digital Gene Expression Displayer and 
cDNA Digital Gene Expression Displayer databases of the Cancer Genome 
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Anatomy Project based on SAGE and EST libraries [99]. Among existing EST 
libraries, 269 libraries of cancerous tissues versus 339 libraries of healthy tissues 
were screened. Among existing SAGE libraries, 78 libraries of cancerous tissues 
versus 182 libraries of healthy tissues were screened. Significance filter was 
adjusted to p<0.05. 59 genes were obtained based on the above criteria. Extracted 
data were checked by using Monochromatic SAGE/cDNA Virtual Northern. Among 
the 59 genes, 8 genes that have a neighboring cancer-testis (CT) gene were chosen 
and expression analyses were made to verify the database data. These 8 genes 
were located at least 30kb and at most 560kb from a CT gene.  
Conventional and Real-Time PCR  
Primer Ts were calculated according to the formula: Tm = 69.3oC + 0.41 (%GC) - 
535/n, where n is primer length. Conventional PCR was carried out under the 
conditions of 94oC for 10 min followed by 35 cycles of 94oC for 60s, appropriate 
melting temperature for 60s, 72oC for 60s, with a final extension at 72oC for 10 
min, in Techgene thermal cycler (Techne), and run on 1.5% agarose gel at 90V for 
45 min. DyNAzyme II HS DNA polymerase (Finnzymes #F-504), dNTP mix 
(Finnzymes #F-560), forward and reverse primers at final concentrations of 0.03 
U/µl, 250 µM, 500 nM, respectively, were used. GAPDH was used as positive 
control. For real-time PCR, efficiency curves of candidate genes were plotted and 
1:5 dilution was chosen. 4 housekeeping genes, GAPDH, 18S rRNA, TFCP2 [100] 
and GOLGA1 [101], were tested as candidates to normalize the real-time data. 
Analyses of these genes by GeNorm program [102] lead to choice of TFCP2 and 
GOLGA1 for normalization. Real-time PCR experiments were carried out in Bio-Rad 
iCycler under the same setup explained above followed by melting curve analyses. 
Sybr Green dye (DyNAmo HS SYBR Green qPCR Kit, Finnzymes #F-410L) was used 
for measurement of DNA amount. Genes were normalized according to delta-delta 
Ct method.  
2.2 Methylation Analyses of Putative TSGs 
Detection of CpG Islands 
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A region including 3000 bases upstream of transcription start sites were analyzed 
for presence of CpG islands by using CpG Island Searcher [103] and CpGPlot [104] 
programs according to the following criteria: Observed/expected ratio > 0.60, 
percent C + percent G > 50.00, length > 200 
Bisulfite Sequencing 
400 ng DNA from HCT15, HCT116, Ls174T, LoVo, Colo205 and Lim1215 cells was 
sodium bisulfite treated with EZ DNA Methylation-Gold Kit (Zymo Research 
#D5005) according to manufacturer’s instructions. 2 µl of 1:10 diluted bisulfite-
modified DNA was amplified by conventional PCR under conditions of 94oC for 10 
min followed by 35 cycles of 94oC for 60s, appropriate annealing temperature for 
60s, 72oC for 60s, with a final extension at 72oC for 10 min, in Techgene thermal 
cycler (Techne), run on 1.5% agarose gel at 90V for 45 min, gel extracted (QIAquick 
Gel Extraction Kit, Qiagen #28704) and sequenced (Iontek). Cytosines within CpG 
dinucleotides were accepted to be methylated if C/T (or G/A) ratio is more than 50 
% among the cell population. Primers used for analyzing sodium bisulfite modified 
DNA are listed in Table 3.    
2.3 Analyses of Higher-Order Chromosomal Structure 
Detection of Inverted Repeats 
Sequences that correspond to regions encompassing NY-ESO-1/LAGE1, CT45 and 
MAGE-A family of genes were analyzed by using the Inverted Repeats Finder 
Program [105] Public Database project. Sequence complementarities were verified 
by MegAlign (DNAStar).  
Chromosome Conformation Capture (3C) 
HCC1937, FOCUS, Colo205, HT29, SK-LC-17 cell lines were grown to 80% 
confluency in RPMI media (PAA #E15-039) supplemented with 10 % FBS (PAA 
#A15-103), 1% peniclllin/streptomycin (Gibco #15140) and 1 % L-glutamine (Gibco 
#25030). Cells were trypsinized (Hyclone #SH30042), centrifuged and resuspended 
in 45 ml of fresh RPMI media. For performing the 3C experiment with tissues, 
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normal thyroid and gall bladder were first dissected, passed through a 70 µm cell-
strainer (BD Falcon #352350), centrifuged and resuspended in 45 ml of fresh RPMI 
media. In presence of 1% formaldehyde, cells were crosslinked for 10 min at RT; 
quenched, resuspended in ice-cold lysing solution supplemented with 100 µl 
complete protease inhibitor cocktail (Sigma #P8340) and homogenized in a 
bounce homogenizer with pestle B. Following wash steps, nuclei from 5x106 cells 
were digested with 30U of appropriate restriction endonuclease, overnight with 
conventional restriction endonucleases (Fermentas BglII #ER0081,EcoRI #ER0271, 
GsuI #ER0462, XceI #ER1471) and for 2 hours with Fast-Digest enzymes 
(Fermentas BglII #FD0074, EcoRI #FD0274, XceI #FD1474). 1x106 restriction-
digested nuclei were used for ligation for 2 hours at 16oC with 30U of T4 DNA 
ligase (Promega #M1804, Fermentas #EL0012). Cross-links were reversed 
overnight at 65oC by Proteinase K (100 µg/ml). DNA was phenol/chloroform 
extracted, ethanol precipitated and resuspended in appropriate amount of TE 
buffer. DNA concentrations were measured at Nano-Drop UV/Vis 
spectrophotometer (Thermo). Chromatin in the absence of formaldehyde and T4 
DNA ligase were used as not cross-linked and unligated negative controls and 
processed similarly in the following steps. 
Final chromatin preparations were analyzed by conventional PCR with the primers 
listed in Table 4 under the setup: 94oC for 10 min followed by 35 cycles of 94oC for 
30s, appropriate annealing temperature for 30s, 72oC for 30s with a final 
extension at 72oC for 10 min, in Perkin-Elmer 9700 thermal cycler. DyNAzyme II HS 
DNA polymerase (Finnzymes #F-504), dNTP mix (Finnzymes #F-560), forward and 
reverse primers were used at final concentrations of 0.03 U/µl, 250 µM, 500 nM, 
respectively. Samples were run on 1.5 % agarose-gel at 90V for 45 min. Detected 
bands were gel extracted and sequenced for verification. 
Analyzed interactions were normalized for bias in 3C efficiency to a control 
interaction at the γ-actin region [106]; and for PCR-bias of primer pairs to 
interactions of similarly processed BAC (bacterial artificial chromosome) clones 
RP11-103M23 (for NY-ESO-1 region), RP11-111C16 and RP11-299H1 (for CT45 
region).  
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5-Aza-2’-deoxycytidine Treatment  
HT29 and Colo205 cells were treated for 2 days with 5-Aza-2’-deoxycytidine 
(Sigma #A3656) at 1 µM final concentration in RPMI media. The cells were then 
washed with PBS and used for 3C analysis at subsequent steps. RNA from AZA-
treated and -untreated cells was also isolated and expression levels were analyzed 
by RT-PCR (Finnzymes DyNAmo cDNA Synthesis Kit #F-470). 
 
Table 1 Genetic information regarding selected putative TSGs 
Gene Name Accession # 
Chromosomal  Gene Length  mRNA length 
Region (bp) (bp) 
Aminolevulinate, 
delta-, synthase 2 
(sideroblastic/hypoch
romic anemia) 
(ALAS2) 
NT_011630.14  Xp11.21 21924 1941 (NM_000032) 
      1830 (NM_001037967) 
      1937 (NM_001037968)  
      1745 (NM_001037969)
†
 
Cerebellar 
degeneration-related 
protein 1 (CDR1) 
NT_011786.15  Xq27.1-q27.2 1299 1299 (NM_004065.2) 
        
Gamma-aminobutyric 
acid (GABA) A 
receptor, alpha 3 
(GABRA3) 
NT_011726.13  Xq28 283304 2785 (NM_000808) 
        
Hypothetical protein 
LOC286411 
NT_011786.15  Xq27.1 20529 1607 (XM_932619.3) 
        
Ras-related GTP 
binding B (RRAGB) 
NT_011630.14  Xp11.21 41029 2217 (NM_016656) 
      2133 (NM_006064)
†
 
Solute carrier family 9 
(Na+/H+ exchanger), 
member 6 (SLC9A6) 
NT_011786.15  Xq26.3 61843 4742 (NM_001042537) 
      4646 (NM_006359)
†
 
SLIT and NTRK-like 
family, member 2 
(SLITRK2) 
NT_011681.15  Xq27.3 8011 5022 (NM_032539) 
        
Zinc finger, CCHC 
domain     containing 
12 (ZCCHC12) 
NT_011786.15  Xq24 3145 2212 (NM_173798.2) 
        
† the isoforms used when indicating amplified regions for gene expression 
analyses 
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Table 2 Primers used for expression analyses 
Gene 
Name 
Sequence of Primer Region amplified and 
amplicon length (bp) 
Tm 
(oC) 
ALAS2 
F: 5`- AGGGTGCGAGATTTACTCAGAC 
R: 5`- ATTCTAGAGCTCCAGAGAGCAC 
678 - 1156 (479) 
 
65 
65 
CDR1 
F:5`- TCGGAAGCTATGGATTTGAGGG 
R:5`- TCCAGCCAATATATGTCTTCCTGAAG 
400 - 802 (403) 
 
65 
66 
GABRA3 
F:5`- GCTAGTAAGATCTGGACACCG 
R:5`- TTCCACGGATTTGTTCTTTCCGAG 
666 - 935 (270) 
 
65 
66 
LOC286411 
F:5`- GGTGAAAGACACTCATCCAGATG 
R:5`- TCGGTGTGCCTTTGGATATGTC 
135 - 516 (382) 
 
66 
65 
RRAGB 
F:5`- TCTGGTAAGACCAGCATGAGG 
R:5`- GGAAGATGTTGTCCCGTTGG 
733 - 928 (196) 
 
65 
65 
SLC9A6 
F:5`- CTTGGGTCTATCCTAGCATACG 
R:5`- TCGCTGTGACATCAAAGGTGTG 
561 - 897 (337) 
 
65 
65 
SLITRK2 
F:5`- CCCACTTCCTGAAGATGCTAAAC 
R:5`- CACCTTCGGTGTCAACTCAG 
1333 - 1585 (253) 
 
66 
65 
ZCCHC12 
F:5`- CTTGAATTCTGTGCAGCTGATTGC 
R:5`- ACACGTGCAATGATGCTAGCC 
204 - 496 (293) 
 
66 
65 
 
 
Table 3 Primers used for bisulfite sequencing experiments 
Gene 
Name 
Sequence of Primer 
Region amplified and 
amplicon length (bp) 
Tm 
(oC) 
 
# of 
CpGs 
 
ALAS2 
F: 5`- GTAGTAAGTTTTGGGTGGGAAGTTG 
R: 5`- CTCCCCTTTTACTAACAACCTCTTC 
(+4865) to (+5188) of TSS 
(324) 66 
66 
3 
 [(-99) to (+225) of         
3rd exon] 
CDR1 
F: 5`- ATTGGGTAGTTGTTGGAAGATATGAAG 
R: 5`- CTTCCATCAAATTAATATCTTCCAACCTAC 
(-9) to (+334) of TSS (343) 
  
65 
65 
8 
  
ZCCHC12 
F: 5`- AGTTTAGGGAGAAGGGAYGG 
R: 5`- CCRCCCAATACTAATAAATCTTCCC 
(-263) to (+249) of TSS 
(512) 
 
65 
66 
41 
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Table 4 Primers used for the 3C assay 
Primer 
number 
Sequence of Primer Tm (oC) 
Amplicon 
length (bp) 
1 5’GGGGAAGCCTAACACACTGG 67 
276 
9 5’TTGCCCAGGCTGGTCTCAC 67 
2 5’AGGAAGGAAGACACAGAGCTG 65 
192 
10 5’CTCCGAAAGTGCTGGGATTATAG 66 
3 5’TGGACTCGTGGCCAGGTTTG 67 
281 
11 5’GGTCTCACCAGGGACAACTG 67 
4 5’TCCTCTAACCGCGTGTGACG 67 
174 
12 5’GGATATTGTTAGTTGTCACAACAGGAC 66 
5 5’AGAGAGCAAGTCAGGACTGTG 65 
336 
7 5’GACAAAATTCGGTCAGCACAAGTAAATAG 66 
6 5’CACCCACATCTGATCTTGAAGTG 66 
173 
8 5’TGCACATTCTCCAACAGGCATC 65 
 
Table 5 Primers used for analyses of non-coding transcripts 
Primer name Sequence of Primer Tm (oC) 
Amplicon 
length (bp) 
A_F 5`- AGCACAGCGTGCAGGTGGAC  69 
209 
A_R 5`- GAGATCTTCCAGCTGCATTCC  65 
B_F 5`- CACTGGCCCCAATTAGGAAGAAC  67 
275 
B_R 5`- GAAGGCCTCATATCCCAATTCTAGC  68 
C_F 5`- CAAGGAAGTTTTGTGGAGTAAGGAAGG  68 
234 
C_R 5`- CTAGGCTTTCTTCAGTCCCCAAAC  68 
D_F 5`- GACAGGGTCACATGCACTTTAC  65 
387 
D_R 5`- CCCGACTTGATCATTACATCGTG  66 
E_F 5' - CAGGGCTGAATGGATGCTGCAGA 70 
337 
E_R 5' - GCGCCTCTGCCCTGAGGGAGG 70 
F_F 5`- TGCATACCCTTCCAGCTGTAGG  67 
365 
F_R 5`- GGAGAAACCTTGGACAATACCCG  67 
G_F 5`- GTTAAATTAGAGCGCATTCATATTGCG  65 
176 
G_R 5`- CTCACCCACTGCAAACATTCAATG  66 
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Table 6 Primers of normalization genes used for all assays 
Primer name Sequence of Primer Tm (oC) 
Amplicon 
length (bp) 
GAPDH_F 5`- GACCACAGTCCATGCCATCACT  67 
454 
GAPDH_R 5`- TCCACCACCCTGTTGCTGTAG 67 
GOLGA1_F 5`- AGATACGGAAGTTAGAGGCCAG 65 
200 
GOLGA1_R 5`- GTCCTTTCTGGCTAATGCCAAAG 66 
TFCP2_F 5`- AAGAAGAGTCGAGTTTGCCTCC 65 
200 
TFCP2_R 5`- CTTCACCAATTTGCCATTAATTTCTGG 65 
18S rRNA_F 5`- CGTGCATTTATCAGATCAAAACCAACC 66 
135 
18S rRNA_R 5`- ATGGTAGGCACGGCGACTAC 67 
γ-actin_F 5' - GCTGTTCCAGGCTCTGTTCC 67 
337 
γ-actin_R 5' - GCGCCTCTGCCCTGAGGGAGG 67 
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3 RESULTS 
3.1 Identification of X-linked CT-Proximal Putative Tumor-Suppressor Genes 
CT genes are known to be induced in many cancer types by hypomethylation of 
promoter or the whole gene. 5-Aza-2’-deoxycytidine induction of CTs verifies 
activation by DNA hypomethylation also. On the other hand, region-specific 
hypermethylation is known to affect many genes, especially tumor suppressors, 
which contributes to tumorigenesis/metastasis through their silencing. Although 
the hypo- and hyper-methylation phenomena are widely referred, exact 
mechanisms of how these controversial events occur are not known yet. The only 
knowledge in hand is about the enzymes exerting these effects in the final steps, 
namely DNMTs and putative de-methylases. In order to approach this mechanistic 
problem in a more detailed manner, we have identified candidate regions on the X 
chromosome which involve both hypomethylated and hypermethylated sites in 
close proximity. Since CT genes are already known to be hypomethylated in 
cancer, we selected CT-proximal genes that are hypermethylated - and thus down-
regulated- in cancer, which we refer as putative tumor suppressor genes (pTSGs). 
X-linked genes that are down-regulated, with respect to their counterparts in 
normal tissues of same origin, in any human cancerous tissue except from 
embryonic and germline origin were identified by analyzing SAGE Digital Gene 
Expression Displayer and cDNA Digital Gene Expression Displayer databases of 
Cancer Genome Anatomy Project based on SAGE and EST libraries [99]. 59 genes 
were obtained based on the above criteria (available in Appendix C). Extracted 
data were checked by using Monochromatic SAGE/cDNA Virtual Northern. Among 
the 59 genes, 8 genes that have a neighboring cancer-testis (CT) gene were chosen 
and expression analyses were made to verify the in silico data, as presented in 
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sections 3.2 and 3.3. The 8 chosen putative TSGs are tabulated in Table 7 together 
with the neighboring CT genes and chromosomal locations.  
 
Table 7 X-linked putative TSGs and the proximal CT genes  
pTSG 
Neighboring CT 
gene(s) 
Approximate distance 
in between (kb) 
Chromosomal 
location 
ALAS2 PAGE2B, PAGE2 44, 58 Xp11.21 
CDR1 SPANXB1 220 Xq27.1 
GABRA3 MAGE-A10, -A6 30, 250 Xq28 
LOC286411 SPANXB1 290 Xq27.1 
RRAGB XAGE4 60 Xp11.21 
SLC9A6 SAGE1, CT45 cluster 50, 80 Xq26-26.3 
SLITRK2 SPANXN1 560 Xq27-27.3 
ZCCHC12 IL13RA1 30 Xq24 
 
 
3.2 Validation of Virtual Data by Conventional RT-PCR  
Firstly, mRNA expression of the 8 genes was tested using conventional RT-PCR in a 
panel of normal tissues. All genes but LOC286411 and SLITRK2 exhibit some 
expression in normal tissues, indicating that their products are not strictly tissue-
specific, although GABRA3 and ZCCHC12 seem to show some tissue specificity 
(Figure 1A). LOC286411 is likely to encode a testis-specific product, thus is 
probably a false-positive of the CGAP database. Those genes that have mRNA 
expression in normal colon and lung tissues were tested in lung and colon cancer 
panels. 2 genes, ALAS2 and CDR1 showed dramatic down-regulation in several 
lung and colon cancer cell lines. Since CDR1 is an intronless gene, negative RT PCRs 
were carried out in DNAse I treated and non-treated samples (Appendix D). 
GABRA3, SLC9A6 and ZCCHC12 genes showed down-regulation only in some cell 
lines; whereas RRAGB did not exhibit significant down-regulation in neither lung 
nor colon cancer cell lines, however, this could occur due to the low-sensitivity of 
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the assay (Figure 1B,C). As a result of the RT-PCR assay, 6 out of the 8 genes, 
namely ALAS2, CDR1, GABRA3, RRAGB, SLC9A6 and ZCCHC12 were selected to be 
putative TSGs and assessed by further experiments.  
 
A) 
 
 
 
 
 
 
 
 
 
 
 
 
B) 
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C) 
 
 
 
 
 
 
 
 
 
 
 
Figure 1 mRNA expression levels of 8 putative tumor suppressor genes on X 
chromosome in normal tissue (A), lung cancer (B) and colon cancer (C) panels, by 
conventional RT-PCR. Two genes, ALAS2 and CDR1 are significantly down-regulated in 
most lung and colon cancer cell lines, while others showed variable down-regulation. 
 
3.3 Validation of Virtual Data by Real-Time RT-PCR  
In order to quantify the mRNA expression levels, we aimed to analyze the 
transcripts of 6 genes whose expression were subject to change, ALAS2, CDR1, 
GABRA3, RRAGB, SLC9A6 and ZCCHC12, by real-time RT-PCR. Firstly, we had to 
identify ‘housekeeping’ genes with mRNA expressions more stable than GAPDH, to 
be used for normalization of expression in our normal tissue, lung cancer and 
colon cancer panels. 4 genes - GAPDH, 18S rRNA, GOLGA1 [101] and TFCP2 [100] - 
were analyzed as candidates for normalization by the GeNorm software and 2 of 
these genes – TFCP2 and GOLGA1 - were shown to be the best choices (Appendix 
E). The background information and basics of GeNorm software are presented in 
Appendix E. After identification of genes for normalization, we analyzed the 5 
31 
 
0
5
10
15
20
25
30
F
o
ld
 d
if
fe
re
n
c
e
 i
n
 e
x
p
re
s
s
io
n
Normal tissues
0
1500
3000
4500
6000
7500
F
o
ld
 d
if
fe
re
n
c
e
 i
n
 e
x
p
re
s
s
io
n
Normal tissues
selected genes by real-time PCR. Data were normalized according to the delta-
delta Ct method. All normal tissues were normalized relative to mRNA expression 
in testis tissue. Lung and colon cancer cell lines were normalized relative to their 
normal counterparts. Figure 2 shows that, these individual genes were expressed 
at similar levels in different healthy tissues with some exceptions: ALAS2 was 
highly expressed in placenta and lung; CDR1 was highly expressed in brain and 
breast; and GABRA3 was highly expressed in brain.  
 
A) ALAS2 
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B) CDR1 
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C) GABRA3 
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D) RRAGB 
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F) ZCCHC12 
 
 
 
 
 
 
 
 
 
 
Figure 2 Quantified expression levels of 6 pTSGs in normal tissues. (A-F) Graphs show 
mRNA expression levels on a large scale (small) and a zoomed-in scale to show details 
(big), where applicable. Graphs show overall mRNA expression levels in other cases.  
 
Secondly, mRNA levels of ALAS2, CDR1, RRAGB and SLC9A6 were analyzed in a 
panel of lung cancers, relative to healthy lung tissue. Strikingly, ALAS2 and CDR1 
were significantly down-regulated in most cell lines (Figure 3A-B). RRAGB and 
SLC9A6 were only slightly down-regulated in some cell-lines (Figure 3C-D). 
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Figure 3 Quantified expression levels of 4 pTSGs in a panel of lung cancer cell lines. 
ALAS2 and CDR1 were significantly down-regulated in most cell lines. 
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Investigation of expression of CDR1, GABRA3, RRAGB, SLC9A6 and ZCCHC12 in 
colon cancer cell lines, relative to healthy colon tissue, yielded similar results. 
CDR1 was significantly down-regulated in all cell-lines (Figure 4A). RRAGB, SLC9A6 
and ZCCHC12 were down-regulated only in some cell lines (Figure 4C-E). GABRA3 
was mostly up-regulated (Figure 4B). Unexpectedly, dramatic down-regulation of 
ALAS2 that was detected by conventional PCR could not be verified by the real-
time PCR assay because of high amount of primer dimers that emerge in the 
absence of ALAS2 transcripts. Performance of probe-based real-time PCR is 
necessary for this purpose. 
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Figure 4 Quantified expression levels of the 6 pTSGs in a panel of colon cancer cell lines. 
Graphs show mRNA expression levels on a large scale (small) and a more zoomed-in 
scale to show details (big), where applicable. CDR1 was significantly down-regulated in 
all cell lines. 
 
As a result of the mRNA expression experiments, we chose ALAS2 and CDR1 as the 
first priority putative TSGs, down-regulated in most colon and lung cancer 
samples. The other 4 genes might also act as pTSGs under specific conditions. 
Consistent down-regulation of GABRA3, SLC9A6 and ZCCHC12 in the same cancer 
cell lines, shown by conventional and real-time RT-PCR experiments, suggests 
these three genes as second priority tumor suppressors, although their down-
regulation is valid to a limited extent. Detailed calculations of the real-time PCR 
assay are presented in Appendix E. 
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3.4 Analysis of Methylation Statuses of Putative TSGs  
As we have identified putative tumor suppressor genes as explained in sections 
3.1 - 3.3, the next question was how these genes were down-regulated in cancer 
cell lines. Since it is known that, several tumor suppressor genes are silenced in 
cancer by promoter hypermethylation; we also hypothesized that the pTSGs might 
be down-regulated via hypermethylation of their promoters. In order to test this 
hypothesis, firstly, promoters and 5’ transcription start sites of the 5 selected pTSG 
genes were analyzed to find possible CpG islands. Two programs, CpG Island 
Searcher [103] and CpGPlot [104] were used. Only 2 out of the 5 genes appeared 
to have CpG islands matching the criteria of observed/expected CpG ratio > 0.60, 
percent C + G > 50.00, and length > 200. The CpG islands of these genes - SLC9A6 
and ZCCHC12 - are presented in Figure 5A-B. ALAS2, CDR1 and GABRA3 do not 
have CpG islands in their promoters, but they have CpG dinucleotides that might 
be subject to methylation (Figure 5C-E). 
The methylation states of the CpG dinucleotides were analyzed by sodium bisulfite 
sequencing. Amplified sites are indicated in Figure 5 and 6A. ALAS2, CDR1 and 
ZCCHC12 were shown to be heavily hypermethylated when down-regulated 
(Figure 6C).  Even the slight difference in expression of the ZCCHC12 gene in 
Colo205 and Lim1215 colon cancer cell lines was reflected by differential 
hypermethylation; more CpG residues in the promoter were methylated in the 
Colo205 cell line in which expression is less (Figure 6B). CpG residues within the 5’ 
region of the CDR1 gene also exhibited this difference.  
In the case of ALAS2 gene, the 5’ site of the 3rd exon - instead of TSS – was 
amplified because the first exon of the ALAS2 gene bears very few CpG residues. 
Therefore, the 3rd exon was chosen instead. The region around the 3rd exon 
contains 6 CpG residues, as compared to the 2 CpGs found close to the genes’ 
transcription start site (Figure 5). The few CpG residues within the amplified 
region were mostly methylated in all cell lines tested (Figure 6B). However, further 
data emcompassing the whole gene might be required to suggest down-regulation 
by hypermethylation.    
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D)  CDR1 
 
 
 
 
E)  GABRA3 
 
 
 
 
 
 
Figure 5 CpG dinucleotides present in the promoter sequences of the 5 pTSGs. (A,B) 
SLC9A6 and ZCCHC12 genes bear classical CpG islands in their promoters. (C-E) ALAS2, 
CDR1 and GABRA3 do not have CpG islands in their promoters. Few CpG dinucleotides 
are shown in red. Gray highlights show the exons and underlined sequences show the 
primers used for sequencing. Transcription start sites are indicated by arrows. 
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A)                       
 
 
 
 
 
 
B)              
 
 
C) 
 
 
 
 
Figure 6 Analyses of methylation states of the ALAS2, CDR1 and ZCCHC12 genes by 
sodium bisulfite sequencing. (A) The exon-intron structure of the genes are shown. Light 
and dark grey boxes denote intron and exons, respectively. Red bars indicate the sites 
of amplification. (B,C) Results of the assay. Tested CpG residues of the three genes are 
hyper-methylated in correlation with the expression levels. Each circle denotes a CpG 
dinucleotide. Open circle: unmethylated, closed circle: methylated. Transcription start 
sites are indicated by arrows. x refers to non-informative data for the specific CpG 
dinucleotide. 
 
Amplified regions of GABRA3 and SLC9A6 genes could not be sequenced 
successfully due to the repeated nucleotides within the regions in question. An 
alternative strategy might be required to analyze these two regions.  
x 
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3.5 Analysis of Higher-Order Chromosomal Structure of CTs  
Our results suggest hypermethylation of DNA as a major factor regulating 
expression of putative TSGs. Cancer-testis genes are already known to be 
regulated by hypomethylation. However, which exact mechanism(s) might result 
in differential DNA methylation of proximal sites is not known. In order to go one 
step beyond, we tried to find the underlying mechanism of CT-TSG difference in 
expression.  
It is known that different sets of histone modifications imply different effects on 
transcriptional regulation, as explained in section 1.2.2. Therefore, the histone 
modifications present at our whole model regions should have been analyzed as a 
primary step. ChIP-Seq data covering the whole genome, generated by Barski and 
colleagues enabled us to analyze the model regions for more than twenty histone 
methylations together with the insulator-binding protein CTCF [47]. Since CTCF 
peaks were not consistent at all sites between CTs and pTSGs, we eliminated the 
possibility of consensus boundary element sequences in these regions. Therefore, 
the possibility of simple, boundary element mediated difference in expression was 
also eliminated.  
The chromatin modification profiles reported by Barski et al. do not contain 
information for any of the classical CT gene regions. This observation (which is due 
to the fact that the Lumina mediated high throughput sequencing analysis discards 
information if more than one of the same DNA sequences are encountered) 
prompted us to focus on the “repeat regions” in which the CT genes are 
contained.   We characterized these repeat regions for multiple CT cluster-regions 
utilizing the Inverted Repeats Finder program [105] and confirmed that CT genes 
were actually organized into large inverted repeats as a result of ampliconic 
duplications. Few examples of such regions are illustrated in Figure 7.  
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A) 
 
 
 
 
 
B) 
 
 
 
 
 
 
C) 
 
 
 
 
 
 
Figure 7 Genetic structure of some CT-containing inverted repeats. (A) The 51 kb-
inverted repeat in the MAGE-A cluster neighboring the GABRA3 pTSG gene. (B) The 36 
kb-inverted repeat in the NY-ESO-1. (C) The 52 kb-inverted repeat in the CT45 cluster 
neighboring the SLC9A6 pTSG gene 
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The inverted repeats overlap with the regions missing histone modifications 
mentioned above, which supports the assay-artifact idea. Since almost all CT 
genes are contained within inverted repeats, we hypothesized that this very 
structure itself could be part of the answer to the question of how CT and pTSG 
regions are separately regulated. Namely, we thought that these inverted repeats 
could form a self recognizing fold or loop. Therefore, in the next step, we aimed to 
demonstrate such a higher-order chromosomal structure formed by these regions 
containing CT genes. However, choosing a pair of chromosomal regions that 
possibly would form a fold/loop is difficult since many members of a given CT 
family can be spread over a very large region within the X chromosome and can 
consist of multiple identical repeats. Thus, we selected the simplest of these, 
namely the NY-ESO-1 inverted repeat region as a model to study the higher-order 
chromosomal structure of CT genes. We employed the chromosome conformation 
capture (3C) assay, which is a biochemical assay to detect intra- and inter-
chromosomal interactions. Although the NY-ESO-1 region does not involve a 
putative TSG, the features of this region might be extrapolated to other CT 
regions, since CT genes are coordinately regulated, probably by same or similar 
mechanisms. 
3.5.1 3C Analysis of the Model NY-ESO-1 Region  
a) Experimental Design 
NY-ESO-1 gene cluster is composed of two-copies of this CT gene on Xq28, and a 
close family member (LAGE-1) forming the third copy. Upon investigation of this 
chromosomal region with the Inverted Repeats Finder program, we identified that 
the two NY-ESO-1 genes were contained within two inverted repeats of ~ 35 kb, 
separated by ~ 21 kb of unrelated DNA. The two repeats are 99.69 % identical. We 
hypothesized that these repeats would interact with each other, possibly forming 
a loop as depicted in Figure 8C. We refer to this structure as ‘looping’ of DNA.  
In order to test if this looping occurs or not, we performed the chromosomal 
conformation capture assay. Briefly, utilizing this technique, DNA is formaldehyde-
crosslinked, digested by appropriate restriction endonucleases, followed by 
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ligation and PCR analysis. An in vivo interaction of DNA is thus demonstrated by 
PCR bands that are otherwise not detectable because distant DNA sites are not 
crosslinked to each other. We designed 3C primers corresponding to sequences 
between, as well as distant to the two inverted repeats. Primer and restriction 
digestion sites used for 3C are shown in Figure 8.  
A)                             
 
 
B) 
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C)       
        
 
 
 
 
 
 
 
 
Figure 8 Investigation of the higher-order chromosomal structure of the NY-ESO-1-
containing IRs. (A) The blue boxes correspond to sequences that form the two IRs.  
Duplicate genes are shown in identical colors. Dashed lines indicate non-annotated 
transcripts that may exist. Primers used for 3C assay are indicated by arrowheads and 
numbers. Odd numbers show the first-round primers, even numbers show the primers 
for nested PCR. # and * denote restriction sites for BglII and EcoRI endonucleases, 
respectively. (B) Detailed view of the NY-ESO-1 IR region. EcoRI and BglII restriction sites 
with distances to the IR, and percent identities of the region are shown.  (C) Expected 
intra-chromosomal interactions for this region and progress of the 3C assay for this 
conformation. Primers in the dashed box recognize EcoRI restriction sites A and B shown 
in (B).  
 
If we could show looping within this region, an equally important question would 
be whether the formation of this loop would occur differently between healthy 
and cancerous states. In order to answer these questions, we designed the 3C 
assay using HT29 and Colo205 colon cancer cell lines that do not express CTs as 
models, together with DNA obtained after 5-AZA-2’-deoxycytidine-treatment 
which is known to induce CT gene expression in these cells. LAGE-1 is also a CT 
gene proximal and similar to NY-ESO-1, therefore expression of it was also 
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analyzed.  The 3C assay was performed also on the SK-LC-17 lung cancer cell line 
which is known to express most CT genes. Little amount of healthy gall bladder 
and thyroid tissues were available, and they were included in the investigation of 
big loop outside of the inverted repeats (IRs) NY-ESO-1 and LAGE-1 expression in 
untreated and AZA-treated HT29 and Colo205 cell lines are shown in Figure 9.  As 
can be seen, AZA treatment of the cells did result in de novo NY-ESO-1, as well as 
LAGE-1 expression in both cell lines, albeit at different intensities. 
 
 
 
 
 
 
Figure 9 CT expression levels of the colon cancer cell lines HT29 and Colo205 that were 
used for the 3C analysis. 5-Aza-2’-deoxycytidine treatment induces NY-ESO-1 and LAGE-
1 expression.  
 
b) Chromosomal Juxtapositioning Proximal to the NY-ESO-1 IR 
Results of the 3C assay are presented in Figure 10. When genomic DNA was 
digested with EcoRI and primers # 4 & 12 (with 3 & 11) were used (as shown in 
Figure 8), we were able to observe a 174 bp band for SK-LC-17, the cell line which 
has strong expression for NY-ESO-1, but not for any other cell line or tissue, 
suggesting that this chromosomal region had adopted a conformation juxtaposing 
those regions complementary to the primers (Figure 10A). The same band was 
observed for the HT29 cell line only after it had been treated with AZA, suggesting 
that the formation of this chromosomal conformation occurred only upon DNA 
demethylation in this cell line. A second 3C experiment, aimed to demonstrate the 
same chromosomal conformation was performed with a different set of primers 
(Figure 10B). This time, we observed a band only for AZA treated HT29, but not for 
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SK-LC-17, most likely suggesting that the primers used for this experiment were 
not as efficient or that the conformation they could detect occurred less 
efficiently.  A third set of primers (# 6 & 8) were designed that would demonstrate 
chromosomal juxtapositioning of the NY-ESO-1 inverted repeats regions located 
proximally (see Figure 8). Surprisingly, these primers were able to amplify a band, 
suggestive of chromosomal juxtapositioning in all cell lines 
Because of the limited availability of normal tissue RNA, those were not included 
in this experiment. For all experiments controls included a known interaction at 
the gamma-actin region [106]; and the BAC clone RP11-103M23 which was used 
as a template (Figure 10D). To ensure that the obtained PCR products 
corresponded to the chromosomal regions we anticipated, they were gel purified 
and sequenced. Sequencing results are given in Appendix F and show that the 
bands correspond exactly to the regions shown in Figure 8. 
Our results, thus, demonstrate the presence of chromosomal juxtapositioning of 
regions neighbouring the NY-ESO-1 containing repeat regions. We believe that this 
juxtapositioning is due to a linear interaction between duplicated regions that 
abruptly ends towards both ends of the repeat due to the following reasons. 
Firstly, any interaction 5’ to the restriction site cannot be detected by this method. 
Secondly, although it is difficult to tell if and if where exactly within the repeat 
region the above proposed interaction occurs, it has to occur within a site after (3’ 
to) the end of the primers and before (5’ to) the first EcoRI (or BglII) site 
downstream to the primer sites, which falls within the repeat (Figure 8).  That two 
different sets of primers have both been able to amplify a product from this region 
strengthens this observation.  Interestingly, robust bands demonstrating the 
juxtapositioning of the repeat regions near the opposite end of the IR, namely the 
ends which are separated by about 21 kb of non-repeated sequences (Figure 8), 
could be demonstrated for each sample tested.  Our results, thus, demonstrate 
the presence of two chromosomal juxtapositioning events, one that involves both 
distal ends of the NY-ESO-1 IR, forming a “big loop”, and one that possibly results 
in the looping out of the sequence between the two IRs, forming a “small loop”.   
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c) Chromosomal juxtapositioning correlates with NY-ESO-1 expression 
Figure 10 A and B show that formation of the “big loop” can be detected in a cell 
line that express NY-ESO-1 (SK-LC-17) and in HT29 cells upon AZA treatment. In 
cells or tissues where no NY-ESO-1 expression is detected loop formation is also 
not detected. This suggests a direct relation between the big loop formation and 
NY-ESO-1 expression.  For Colo205, however, despite efficient AZA mediated NY-
ESO-1 mRNA induction is observed, the presence of the big loop was never 
observed. As will be discussed further, this might be due to the following: 1. Loop 
formation correlates with NY-ESO-1 expression but is not the rule; 2. Loop 
formation occurs for Colo205 at lower efficiency and the primers utilized for its 
detection are partially effective; 3. The big loop formation contains either two NY-
ESO-1 IRs or one NY-ESO-1 IR and the LAGE homologous region, and these occur at 
different rates in both cells.    
In summary, our results for the first time suggest a correlation of CT gene 
expression and a particular chromosomal conformation that can respond to 
variations of DNA methyl content. 
 
A) Primers 2-10 
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B) Primers 4-12 
 
                     
 
 
 
 
 
 
C) Primers 6-8                                                                 D) BAC clone control 
 
 
 
 
 
 
 
 
Figure 10 3C assay for the NY-ESO-1 region. (A): PCR of the same DNA with primers # 3 & 
11,reamplified using primers # 4 & 12. (B) PCR of crosslinked and EcoRI digested/ligated 
genomic DNA with primers # 1 & 9, reamplified using primers # 2 & 10 (see Figure 8 for 
primer information). (C) PCR of BglII digested/ligated DNA using primers # 6 & 8. (D) 
Control PCR reactions. UT: untreated; G0: cells synchronized at G0; FA: formaldehyde. 
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d) Chromosomal Looping Correlates with Expression Originating within the 
Loop 
The above described data strongly supports our hypothesis that the NY-ESO-1 IRs 
interact linearly, forming a big and a small loop. Since the constituents of this loop 
are thus identical DNA sequences, fine mapping of the exact start and end points 
of this linear interaction utilizing 3C cannot be performed. However, should this 
linear interaction occur, then other transcripts that originate within these IRs 
would be expected to show an expression pattern similar to NY-ESO-1 and not like 
those genes outside the IRs. To test for this hypothesis we searched the ENCODE 
data present in the UCSC Genome Browser [112] for the non-coding transcripts 
since there is only one other annotated gene within these IRs (LOC 643894). 
Various annotated ncRNAs as well as the genes mapped to this region are shown 
in Figure 11. 5RACE122 and 5RACE117, for example, are ncRNA molecules which 
were detected in brain and colon, respectively and cover large regions.   In order 
to analyze the whole IR region for the presence of ncRNA transcripts - either 
annotated or non-annotated -, 4 primer pairs were designed from within the IR 
and the spacer DNA (B, D, F, G primers in Figure 12). Primers for detecting the 
mRNA levels of the genes inside the repeat were also designed (A, C and E primers 
in Figure 12). 
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Figure 11 Annotated transcripts in the NY-ESO-1-bearing inverted repeat region; 
ENCODE Project at UCSC Genome Browser. Healthy testis, brain, colon and lung tissues 
together with a HeLa sample are shown. 
 
 
 
 
 
Figure 12. Primer pairs for detecting mRNAs and non-coding RNAs from within the 
inverted repeat(s) (primer pairs A-F) and inside the small loop between the two repeats 
(primer pair G). Primer pairs A, C and E correspond to mRNAs of genes IKBKG, LOC 
643894 AND NY-ESO-1. B, D and F regions correspond to non-coding RNA transcription 
sites. Blue boxes correspond to sequences that form the two IRs.  Duplicate genes are 
shown in identical colors. Dashed lines indicate non-annotated transcripts that may 
exist.    
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The same cell lines with the 3C assay were used for comparison of the results: 
untreated and AZA-treated HT29 and Colo205, and SK-LC-17. Normal lung, colon 
and testis RNAs were also used as reference. PCR results are shown in Figure 13. 
IKBKG (A) primers as well as ncRNA1 (B) primers amplified a product in all samples 
tested, demonstrating discordance with NY-ESO-1 transcription.  We could not 
detect a transcript corresponding to LOC643894 (C). Primers amplifying the two 
ncRNAs flanking the NY-ESO-1 gene, ncRNA2 (D) and ncRNA3 (F) amplified a 
product most prominently in SK-LC-17, but also weakly in normal tissues, and 
interestingly, both ncRNAs were induced by AZA treatment in both HT29 as well as 
Colo205, albeit weekly.  Transcript G was weakly expressed in all three cell lines 
tested but did not show a particular pattern. Therefore, the transcript analysis of 
the NY-ESO-1 regions demonstrates a close correlation of transcription patterns of 
ncRNAs 2, -3 and NY-ESO-1, while transcripts further upstream and downstream to 
these demonstrate a different expression pattern, supporting the hypothesis that 
a common regulatory event encompasses and extends beyond the physical 
boundaries of the NY-ESO-1 gene. Although this common regulatory pattern does 
not seem to prevail throughout the IR, as demonstrated by the behavior of 
transcripts A and B. However, the cumulative data suggests that there are 
common expression patterns within the IRs and that their boundary closely 
correlates with the presence of the IR, at least at one end of the repeat.     
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Figure 13. mRNAs and ncRNAs expressed within the inverted repeat(s) (A-F) and within 
the non-repeated region between the two IRs (G). A=IKBKG; B=ncRNA1; C= LOC 643894; 
D=ncRNA2; E:NY-ESO-1; F=ncRNA3; G=ncRNA4.  
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4  
In this study, our main aim was to understand the mechanism(s) of regulation of 
CT gene expression. Hypo-methylation of DNA is known be one factor reactivating 
CT genes in testis and during carcinogenesis. Histone modifications play unclear 
roles. It is of major interest to understand CT regulation since reactivation of CT 
genes is correlated with poor prognosis of cancer. We approached this question in 
a manner that combines hypo-methylated and hyper-methylated DNA sites under 
the same frame, so that we could observe the gradual or strict passage in between 
these regions. Here, tumor suppressor genes (TSGs) correspond to the hyper-
methylated genes class based on previous studies supporting this idea for the 
cancer model. Focusing on this kind of system would also facilitate to understand 
ectopic and simultaneous DNA (de-)methylation that occurs in cancer. 
Newly Identified Putative Tumor Suppressor Genes 
The necessity to identify model regions containing hypo- and hyper-methylation in 
close proximity leaded us to detect putative TSGs neighboring CT genes on the X 
chromosome. As a result of in silico data mining and expression assays, we here 
suggest five X-linked putative tumor suppressor genes: ALAS2, CDR1, GABRA3, 
SLC9A6 and ZCCHC12. ALAS2 and CDR1 are the genes most significantly down-
regulated in most of the cancer cell lines tested. They were already studied by 
other groups, however literature regarding these two genes is based on their 
associated diseases sideroblastic anemia and cerebellar degeneration [113, 114]. 
Interestingly, histone acetyltransferase p300 and Sp1 proteins were shown to 
regulate ALAS2 expression in erythroid cells [115].  
Tumor suppressor genes are known to be frequently down-regulated by promoter 
DNA hyper-methylation in a wide variety of cancer types. p16INK4a and BRCA1 are 
DISCUSSION 
& FUTURE PERSPECTIVES
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among the mostly referred examples [93]. It was likely that the same mechanism 
could be responsible for down-regulation of our pTSGs, therefore we have initially 
analyzed the methylation levels. Bisulfite sequencing data indicated hyper-
methylation of DNA to be an acting mechanism for reducing expression of the 
ALAS2, CRD1 and ZCCHC12 genes, although only ZCCHC12 gene contained a CpG 
island in its promoter region. Analyzed CpG dinucleotides belonging to ALAS2 and 
CDR1 genes being hyper-methylated suggest aberrant methylation as a powerful 
regulatory mechanism even in the absence of CG-rich sequences. Further 
methylation analyses are though required. Firstly, T/A-cloning-wise amplification 
of the PCR fragments is necessary to screen the methylation rate of the cell 
population. Selection of many clones is an advantage of this method. Sequencing 
of plasmid DNA (of the clones) would also be easier than sequencing the PCR 
product, since faint bands are often obtained as a result of weak amplification of 
sodium bisulfite-treated DNA. Secondly, more DNA samples could be used for 
comparison. Two cell lines were used for each of CDR1 and ZCCHC12 genes (4 cell 
lines for ALAS2); which gives a general idea about regulation however one can 
make more accurate deductions if more cell lines are used. Moreover, healthy 
tissue DNA should better be used to compare the results to cancer cell lines, 
although it is not an obligation. Normal tissue samples can rarely be obtained, thus 
peripheral blood lymphocyte DNA is an alternative control that is easily handled. 
Thirdly, larger DNA sequences within the promoter and within the coding region 
should be screened - by multiple primers if necessary - to learn the target region 
of the DNA methylation machinery. The other two putative TSGs, GABRA3 and 
SLC9A6 genes, should also be analyzed in terms of promoter methylation levels 
either by bisulfite sequencing or by other means like melting curve or COBRA 
(Combined Bisulfite Restriction Analysis) techniques. Bisulfite sequencing of 
amplified regions of these two genes were unsuccessful, probably because of the 
short repeated elements within the regions complicating the sequencing reaction. 
Lastly, investigation of mRNA expression levels of the pTSGs after induction with 
5-Aza-2’-deoxycytidine is necessary to show a direct link between mRNA 
expression and DNA hypermethylation.   
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One critical issue while carrying out bisulfite sequencing is the possibility of PCR 
bias of the designed primers. Since methylated cytosines retain as ‘C’s and 
unmethylated cytosines are converted to ‘T’s during PCR amplification, primers 
could bind to methylated sequences tighter than the unmethylated ones, which in 
turn would seem like the DNA is more methylated in the original sample. The 
resulting conclusions would then be inaccurate and misleading. In order to 
eliminate such situations, each primer pair should be tested to recognize different 
percents of unmethylated/methylated DNA mixtures and improper pairs should be 
avoided.  
We have shown the down-regulation and promoter hyper-methylation of the 
newly identified pTSGs in cancer cell lines, which were necessary experiments to 
be done in order to determine our model sites on the X chromosome. Further 
experiments about understanding the regulation of proximal hypo- and hyper-
methylated regions are discussed below. As we have proposed novel pTSGs, 
another project arises at this point. In order to suggest these genes as TSGs, 
further investigation should be done. Firstly, tumor suppression abilities could be 
assessed in an apoptosis system. Cloning of the genes into mammalian expression 
plasmids is necessary. However, expression from the often-used plasmids is itself 
toxic to cells and complicates the apoptosis assays. Instead, an inducible-plasmid 
system would be utilized and would give more reliable results. In this system, 
verification of the tumor suppression ability could be done first by simply counting 
the number of viable cells before and after induction; and also by analyzing the 
levels of apoptotic proteins activated/anti-apoptotic proteins repressed after 
induction. Invasion assays could also be carried out to observe any effects on the 
metastatic abilities.   
Alteration of Higher-Order Chromosomal Structure Affecting NY-ESO-1 
Expression  
As previously mentioned, our main focus was on understanding the regulation of 
CT gene expression by investigating the determined in vivo model system on the X 
chromosome. Initially, we tended to find candidate boundary elements in 
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between CT genes and pTSGs, as this would be an expected situation when two 
proximal sites are oppositely regulated. Boundary element-mediated insulation of 
chromosomal marks such as DNA methylation and histone modifications have 
been shown to be valid for many cases and can be found in literature [116, 117]. 
As demonstrated in Figure 14, this idea would perfectly fit into our model since 
permissive and repressive histone modifications are likely to play key roles in 
regulation of CTs and pTSGs in cancer, respectively. Testing of this idea was done 
by utilizing genome-wide chromatin immunoprecipitation data for the CTCF 
protein because CTCF, apart from its role as a transcription factor, binds to many 
insulator elements, thus could be regarded as an ‘insulator protein’ [118].  
 
 
 
 
 
 
Figure 14 Model of boundary element-mediated difference in regulation of CT and TSG 
gene expression 
 
As a result of the analysis of CTCF binding, no consensus boundary elements could 
be found within our model regions. This unexpected result raised questions about 
the types and levels of histone modifications at these sites. Analyzing the same 
ChIP-Seq data from Barski et al. [47], we came across other unexpected results 
such that none of more than twenty histone methylations were detected around 
CT gene clusters. Absence of histones at these sites resembled absence at sites of 
DNA repeats. As the next step, some sample CT clusters were investigated under 
the Inverted Repeats Finder program [105] and clusters of multi-copy CT genes 
were found to be organized into large inverted repeats as a result of ampliconic 
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duplications on the X chromosome. This explains the high number of pseudogenes 
of cancer-testis genes.     
The repeat-embedded structure of the CT genes, exemplified in Figure 7 for MAGE 
and CT45 clusters and NY-ESO-1, could be a candidate regulator of CT gene 
expression by inducing changes in chromosomal structure. It is also a candidate 
mechanism that leads to differences in our model CT/pTSG regions, because the 
pTSGs lie outside the inverted repeats. To test these hypotheses, we employed the 
biochemical 3C assay which is useful to gather information about the higher-order 
conformations of chromatin. We used untreated and 5-Aza-2’-deoxycytidin-
treated HT29 colon cancer cell line, SK-LC-17 lung cancer cell line and healthy 
thyroid and gall bladder tissues whenever possible. As a result of all experiments, 
we observed changes in higher-order structure of chromatin in the NY-ESO-1-
containing inverted repeat region on Xq28. As illustrated in the model (Figure 15), 
the two inverted repeats spatially converge to each other in the 5-Aza-2’-
deoxycytidin-treated HT29 cell line and in the SK-LC-17 cell line, which both have 
high NY-ESO-1 expression. This ‘large looping’ is not observed in any of the 
untreated HT29 cell line and healthy tissues. Only the ‘small loop’ between the 
inverted repeats is observed, however this loop is observed in all cases tested 
(Figure 10), which means that it does not play a regulatory role on this system. The 
large looping interaction is also likely to correlate with the non-coding RNAs 
detected to be transcribed within the repeats when NY-ESO-1 is also transcribed 
(Figure 13).  
 
 
 
 
 
 
NY- 
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Figure 15 Model regarding epigenetic regulation of CT gene expression: Involvement of 
changes in higher-order chromosomal structure  
 
We thus have a model regarding epigenetic regulation of CT gene expression, in 
which chromosomal structure is the key player for now. Working on this model by 
manipulating different proteins and/or pathways would produce high amount of 
data and contribute to the understanding of CT gene regulation.  
Before passing to further experiments to be done on this system, the weaknesses 
of the results demonstrated here should be discussed. First of all, the 3C assay is 
an extremely delicate assay. It combines many techniques like formaldehyde-
crosslinking, restriction digestion, ligation and purification of DNA and is followed 
by PCR experiments with many different primers. The complicated nature of the 
whole assay and the difficulty to handle in vivo interactions of DNA brings 
sensitivity problems. Even technical PCR replicates do not give the same results all 
the time. To overcome these problems; firstly a probe-based real-time system 
should be used for PCR analyses. Sybr green based real-time systems are useless 
for this purpose since many weak background interactions would create high 
degree of noise. The probe-based system would bring many advantages: Weak or 
delicate interactions that cannot be detected by conventional PCR can be detected 
by the sensitive probe-based system. For example, we could not detect any 
difference in the NY-ESO-1 region between untreated and AZA-treated Colo205 
cell lines, which indeed have difference in CT expression. On the other hand, using 
a probe-based real-time PCR system would enable to calculate the interaction 
frequency of the region [119]. For this purpose, first of all a wider area to the 
outside of the inverted repeats from both sides should be screened by designing 
new primers corresponding to these sites. After performing real-time PCRs with 
the desired samples and BAC controls, sample data should be normalized to BAC 
data to give interaction frequency of the looping. An actual loop is the one which 
gives higher interaction frequency (a peak) as the primers approach to loop from 
both sides. Lastly to overcome the sensitivity problems, three biological replicates 
should be done as usual and one should pay attention at all steps. Usage of male 
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cells should be preferred in order to avoid complexity coming from X chromosome 
inactivation in female cells. The SK-LC-17 and Colo205 cell lines are already male 
cell lines, however HT29 is a female cell line and although the chromosome 
conformation changes upon induction with 5-Aza-2’-deoxycytidine, comparison of 
male and female cell lines might raise artifacts.    
In this study, we only designed probes against the start and end points of the 
repeats to have a general idea if they converge or not. Therefore, we currently do 
not know if the arms of the inverted repeat completely touch each other or not. 
Answering this question is not easy by using the 3C assay since primers cannot be 
designed because of the high degree of identity between the arms. Therefore, 
another technique needs to be applied both to understand the intra-structure of 
the repeat arms and also to verify the 3C data. Visual techniques are the most 
commonly used ones when studying on DNA repeats. Two-color DNA in situ 
hybridization or FRET (Fluorescence Resonance Energy Transfer) techniques could 
be applied to gather in vivo data by fluorescent microscopy. AFM/SFM 
(Atomic/Scanning Force Microscopy) is another choice but would only give in vitro 
data.  
Once the looping interaction is shown by performing probe-based real-time 
experiments, characterization of the protein complexes that mediate the looping 
should be done in order to fully understand the components of the system. RNAi 
pathway is a candidate player in this system since non-coding RNAs are 
transcribed from inside the repeat arms. Knocking down some critical components 
of the RNAi machinery, like Dicer or Argonaute, and then analyzing any alteration 
in looping by 3C is a choice. Moreover, ChIP technique could be employed to 
detect proteins bound to the loop. Antibodies against CTCF, BORIS and Sp1 
proteins can be initially used because of literature suggesting their regulatory roles 
on NY-ESO-1 expression [24, 25]. Once the protein complex is pulled up by a 
known protein component, the whole complex can be characterized by co-IP, 
mass spectroscopy, chromatography or other proper methods.  
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The results shown in Figure 10 leading to our model (Figure 15) were gathered 
from the NY-ESO-1-bearing inverted repeat. The simplicity of this region - that it 
bears only two copies of a CT gene - was the reason why we worked on this 
system. If all the above experiments are done and the acting proteins can be 
characterized; same assays would be extended to other, more complex CT regions 
also. This is easier to perform after characterization of protein components 
because ChIP technique would facilitate the analysis. Visual techniques are also 
more powerful than the 3C assay. We tried to apply the 3C assay to the MAGE and 
CT45 clusters shown in Figure 7 also, however could not obtain consistent results 
possibly because of complex intra-chromosomal interactions of the genes 
embedded in the repeat. Application of same analyses to many CT regions is 
necessary to support the observation that CT genes are coordinately regulated 
[11]. If not all, many of the CT clusters are expected to be regulated by same 
pathways. Conclusions and hypotheses about CT regulation in general are 
discussed below.  
Epigenetic Regulation of Cancer-Testis Gene Expression 
Combining our data with the ones in literature provides enough background to 
hypothesize a general model of CT regulation. Below is a summary of known facts 
and our results about regulation of CT gene expression: 
 CT genes are re-activated in cancer cells by selective demethylation of 
promoter DNA [12, 32-35]. 
 Histone acetylation plays role in modulating CT gene expression [32, 35]. 
 Acetylation-induced transcription is required for active DNA demethylation 
of CT genes, resulting in their reactivation [35]. 
 CT genes are coordinately expressed and are correlated with poor 
prognosis in cancer (at least in non small cell lung cancer) [11]. 
 Members of the MAGE-A CT family, clustered in a large inverted repeat on 
the X chromosome, are coordinately expressed [120]. 
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 Non-coding RNAs are transcribed from sites of CT gene clusters; shown by 
us for the NY-ESO-1 region, found in literature for GAGE region and also 
shown for SSX cluster (unpublished data) [35]. 
 Expression of NY-ESO-1 genes overlaps with expression of non-coding 
RNAs inside the inverted repeat arms. 
 Change in expression profile of NY-ESO-1 gene leads to alteration of 
higher-order chromosomal structure; or vice versa. 
 Effects of differential chromosomal structure and hypomethylation (that 
induces CTs) are likely to be restricted to the inverted repeat region, since 
genes outside the repeats are either constantly expressed or down-
regulated in cases when CT genes are up-regulated. 
 Transcription factors BORIS, CTCF and Sp1 bind to promoters of CT genes 
and modulate their expression [24, 25]. 
 CT antigens are capable of interacting with each other, as MAGEC1 and NY-
ESO-1 do [27]. 
With these information in hand, such a model about regulation of CT gene 
expression is proposed here:  
Improperly functioning epigenetic machinery in cancer cells leads to 
acetylation of histones and other permissive histone modifications at 
sites of CT clusters, which induces transcription of ncRNAs within the 
repeat area. Transcription itself or ncRNAs processed in the RNAi pathway 
mediate demethylation of the promoter (or the whole area), which in 
turn results in reactivation of CT genes. Alteration of chromosomal 
structure in the form of looping occurs either as a cause or as a 
consequence of transcription of ncRNAs; so that factors regulating CT 
gene expression like BORIS, CTCF and Sp1 can bind to the CT promoter 
and help express CTs that are clustered together. Many CT gene families 
are clustered into repeat regions, thus the same conditions apply, to 
induce their coordinate expression. Since CT genes occupy large regions 
on X chromosome, activation of them is regarded as an immediate sign of 
improper epigenetic environment within cancer cells. 
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Working on this model would bring important understanding in operation of the 
epigenetic systems within the cell, which all are indeed connected to each other 
through shared components. Since repeat-based and non-coding RNA-containing 
silencing events are not specific to CT genes and are valid for many other sites, 
tackling the CT problem aids in clarification of the much more general question of 
how epigenetic mechanisms relate to each other and why they are misregulated in 
cancer.   
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APPENDIX A: CURRENT LIST OF CANCER-TESTIS GENES 
 
All human genes listed as cancer-testis (CT) genes till 2007 are presented below 
together with chromosomal locations and numbers of family members [10]. 
 
CT Number Family Name 
Human 
Chromosome 
Human Gene 
Number 
CT1 MAGEA X 13 (0) 
CT2 BAGE 5, 7, 9, 18, 21 7 (0) 
CT3 MAGEB X 7 (1) 
CT4 GAGE X 16 (0) 
CT5 SSX X 14 (0) 
CT6 CTAG X 3 (0) 
CT7 MAGEC X 2 (0) 
CT8 SYCP1 1 1 (0) 
CT9 BRDT 1 1 (0) 
CT10 MAGEE X 2 (2) 
CT11 SPANX X 11 (0) 
CT12 XAGE X 14 (0) 
CT13 DDX43 6 1 (0) 
CT14 SAGE X 1 (0) 
CT15 ADAM2 4, 8 2 (0) 
CT16 PAGE X 7 (0) 
CT17 LIPI 21 2 (0) 
CT21 CTAGE 
2, 6, 7, 9, 10, 
13, 14, 18 21 (12) 
CT24 CSAG X 4 (0) 
CT25 DSCR8 21 2 (0) 
CT26 DDX53 X 1 (1) 
CT27 CTCFL 20 1 (0) 
CT28 LUZP4 X 1 (0) 
CT29 CASC5 15 1 (0) 
CT30 TFDP3 13, 15, X 4 (3) 
CT32 LDHC 11 1 (0) 
CT33 MORC1 3 1 (0) 
CT34 DKKL1 19, 20 2 (1) 
CT35 SPO11 20 1 (0) 
CT36 CRISP2 6 1 (0) 
CT37 FMR1NB X 1 (0) 
CT38 FTHL17 X 4 (4) 
CT39 NXF2 X 2 (0) 
CT41 TDRD 6, 10 2 (0) 
78 
 
CT Number Family Name 
Human 
Chromosome 
Human Gene 
Number 
CT42 TEX15 8 1 (0) 
CT43 FATE1 X 1 (0) 
CT44 TPTE 13, 21, Y 4 (0) 
CT45 CT45 X 6 (0) 
CT46 HORMAD1 1, 6 2 (1) 
CT47 LOC255313 X 12 (0) 
CT48 SLCO6A1 5 1 (0) 
CT49 TAG 5 1 (0) 
CT50 LEMD1 1 1 (0) 
CT51 HSPB9 17 1 (1) 
CT53 ZNF165 6 1 (0) 
CT54 SPACA3 17 1 (0) 
CT55 CXorf48 X 3 (0) 
CT56 THEG 19 1 (0) 
CT57 ACTL8 1 1 (0) 
CT58 NALP4 19 1 (0) 
CT59 COX6B2 19 1 (0) 
CT60 BC047459 15 2 (0) 
CT61 CCDC33 15 1 (0) 
CT62 BC048128 15 1 (0) 
CT63 PASD1 X 1 (0) 
CT65 TULP2 19 1 (0) 
CT66 AA884595 7 1 (1) 
CT68 MGC27016 4 1 (0) 
CT69 BC040308 6 1 (0) 
CT71 SPINLW1 20 1 (0) 
CT72 TSSK6 19 1 (1) 
CT73 ADAM29 4 1 (0) 
CT74 CCDC36 3 1 (0) 
CT75 BC033986 2 1 (0) 
CT76 SYCE1 10 1 (0) 
CT77 CPXCR1 X 1 (0) 
CT78 TSPY1 Y 14 (0) 
CT79 TSGA 2, 21 3 (0) 
CT81 ARMC3 10 1 (0) 
CTNA PRAME 1, 22 36 (0) 
  
Numbers in brackets denote the number of intronless gene copies, which in the 
case of multi-exon genes may indicate putative retrocopy genes. PRAME family 
has not yet been officially designated as CT.  
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APPENDIX B: 
CURRENT LIST OF HISTONE-MODIFYING ENZYMES [45] 
 
Enzymes that modify histones Residues modified 
Acetyltransferases 
HAT1 H4 (K5, K12) 
CBP/P300 
H3 (K14, K18), H4 (K5, K8), 
H2A (K5), H2B (K12, K15) 
PCAF/GCN5 H3 (K9, K14, K18) 
TIP60 H4 (K5, K8, K12, K16), H3K14  
HB01 (ScESA1, SpMST2) H4 (K5, K8, K12) 
ScSAS3 H3 (K14, K23) 
ScSAS2 (SpMST2) H4K16 
ScRTT109 H3K56 
Deacetylases 
SirT2 (ScSir2) H4K16 
Lysine Methyltransferases 
SUV39H1 H3K9 
SUV39H2 H3K9 
G9a H3K9 
ESET/SETDB1 H3K9 
EuHMTase/GLP H3K9 
CLL8 H3K9 
SpClr4 H3K9 
MLL1 H3K4 
MLL2 H3K4 
MLL3 H3K4 
MLL4 H3K4 
MLL5 H3K4 
SET1A H3K4 
SET1B H3K4 
ASH1 H3K4 
Sc/Sp SET1 H3K4 
SET2 (Sc/Sp SET2) H3K36 
NSD1 H3K36 
SYMD2 H3K36 
DOT1 H3K79 
Sc/Sp DOT1 H3K79 
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Enzymes that modify histones Residues modified 
Pr-SET 7/8 H4K20 
SUV4 20H1 H4K20 
SUV420H2 H4K20 
SpSet 9 H4K20 
EZH2 H3K27 
RIZ1 H3K9 
Lysine Demethylases 
LSD1/BHC110 H3K4 
JHDM1a H3K36 
JHDM1b H3K36 
JHDM2a H3K9 
JHDM2b H3K9 
JMJD2A/JHDM3A H3K9, H3K36 
JMJD2B H3K9 
JMJD2C/GASC1 H3K9, H3K36 
JMJD2D H3K9 
Arginine Methyltransferases 
CARM1 H3 (R2, R17, R26) 
PRMT4 H4R3 
PRMT5 H3R8, H4R3 
Serine/Threonine Kinases 
Haspin H3T3 
MSK1 H3S28 
MSK2 H3S28 
CKII H4S1 
Mst1 H2BS14 
Ubiquitilases 
Bmi/Ring1A H2AK119 
RNF20/RNF40 H2BK120 
Proline Isomerases 
ScFPR4 H3P30, H3P38 
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APPENDIX C: 
X-LINKED GENES DOWNREGULATED IN CANCER ACCORDING 
TO ANALYSES OF SAGE/EST LIBRARIES 
 
Gene Name  
Location on 
Chromosome X 
AFF2 Xq28 
AKAP4 Xp11.2 
ALAS2 Xp11.21 
ARHGAP4 Xq28 
ARSF Xp22.3 
ATP2B3 Xq28 
BGN Xq28 
CACNA1F Xp11.23 
CD99L2 Xq28 
CDKL5 Xp22 
CDR1 Xq27.1-27.2 
CHRDL1 Xq22.3 
CLCN4 Xp22.3 
CNKSR2 Xp22.12 
CYBB Xp21.1 
F9  Xq27.1-27.2 
FHL1 Xq26 
GABRA3 Xq28 
GATA1 Xp11.23 
GDI1 Xq28 
GPM6B Xp22.2 
GPRASP2 Xq22.1 
IDS Xq28 
IL3RA Xp22.3 (Yp11.3) 
LAMP2 Xq24 
LOC286411 Xq27.1 
MAOB Xp11.23 
MBTPS2 Xp22.1-22.2 
MCF2 Xq27 
Gene Name  
Location on 
Chromosome X 
MGC39900 xq22.2 
MPP1 Xq28 
MSL3L1 Xp22.3 
OPN1LW Xq28 
P2RY8 Xp22.33 
PDZD4 Xq28 
PEPP-2 Xq24 
PLAC1 Xq26 
PLP1 Xq22 
PNCK Xq28 
PNMA3 Xq28 
PORCN Xp11.23 
PRRG1 Xp21.1 
RGN Xp11.3 
RP11-393H10.2 Xp22.12 
RP13-102H20.1 Xq26.1 
RP6-166C19.1 Xq24 
RRAGB Xp11.22 
RS1 Xp22.2-22.1 
SAT1 Xp22.1 
SEPT6 Xq24 
SLC9A6 Xq26.3 
SLITRK2 Xq27.3 
SMPX Xp22.1 
SYN1 Xp11.23 
SYP Xp11.23-11.22 
TLR8 Xp22 
TSC22D3 Xq22.3 
WAS Xp11.4-11.21 
ZCCHC12 Xq24 
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APPENDIX D: 
NEGATIVE-RT CONTROLS 
 
In order to make the down-regulation of the intronless gene CDR1 sure, negative-
RT PCRs were carried out. Indeed, the initially DNaseI-untreated RNA samples 
were contaminated with genomic DNA, which was eliminated after DNaseI 
treatment. Down-regulation was more clearly demonstrated by amplification of 
the DNaseI-treated samples (Figure E1).  
                       
 
 
 
 
 
 
Figure E1 Negative-RT controls and PCR amplifications of the CDR1 gene on 
DNaseI-treated and -untreated RNA  
 
Negative-RT controls were also needed for verification of non-coding RNAs that 
were demonstrated in Figure 13. As shown in Figure E1, normal colon and other 
normal tissue RNAs (Ambion) do not contain any genomic DNA. Negative-RT PCRs 
were also done for GOLGA1, TFCP2 and IKBKG mRNAs and no bands 
corresponding to gDNA amplification were detected (Figure E2). On the other 
hand, bands for ncRNA were seen in amplification of normal tissue RNAs (Figure 
13), some of which were not detected in untreated Colo205 and HT29 samples. As 
a result, we can conclude that there is not any gDNA contamination in HT29, 
Colo205 and SK-LC-17 cancer cell line samples and detected bands correspond to 
ncRNA. 
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Figure E2 Negative-RT controls of GOLGA1, TFCP2 and IKBKG genes.  
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APPENDIX E: REAL-TIME PCR EQUATIONS & CALCULATIONS 
A) CALCULATION OF EFFICIENCIES 
For calculation of amplification efficiencies, 5- or 10-fold dilutions of brain cDNA 
were used for all genes. Samples were analyzed under same conditions by using 
Sybr Green dye and efficiency graphs were plotted according to the obtained data 
(Figures F2 and F3). Samples were also run on 1.5% agarose gel as shown in Figure 
F1.  
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Figure F1 PCR data for calculation of amplification efficiencies. Individual genes 
are indicated above the gel images. 
 
Efficiency graphs of candidate reference genes and genes in question 
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Figure F2 Efficiency graphs of the candidate reference genes. Individual genes 
are indicated inside the plot area. 
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Figure F3 Efficiency graphs of the genes in question. Individual genes are 
indicated inside the plot area. 
 
Amplification efficiencies (E) of genes were calculated according to equation (1). 
E≥2.0 was taken as 2.0 and results are tabulated in Table F1.   
E = D (1/m)   (1) 
Where  D is fold-dilution of cDNA 
 m is the slope of the trend line of data 
 
Table F1 Amplification Efficiencies of Real-Time PCR primers of Given Genes 
REFERENCE GENES 
Gene Name E value 
GAPDH 1.9 
TFCP2 2.0 
18S rRNA 2.0 
GOLGA1 1.9 
GENES IN QUESTION 
Gene Name E value 
ALAS2 2.0 
CDR1 2.0 
GABRA3 2.0 
RRAGB 2.0 
SLC9A6 2.0 
ZCCHC12 2.0 
y = 2,7829x + 18,76
R² = 0,9908
15
20
25
30
35
40
C
t
Fold-dilution
GABRA3
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B) DETERMINATION OF HOUSEKEEPING GENES 
After calculating the efficiencies of the candidate reference genes, quantities of 
expression were calculated as in equations (2-3).  
Q = EdeltaCt  (2) 
Q = E(minCt - sampleCt)  (3) 
GeNorm software finds the most stable of given reference genes according to the 
variation in Q values. Expression of our 4 candidate reference genes, 18S rRNA, 
GOLGA1, GAPDH and TFCP2 were quantified in a normal tissue panel and Q values 
were entered to the program. Outputs are presented in Figures F4 and F5. TFCP2 
and GOLGA1 were selected as most stable genes, followed by GAPDH and 18S 
rRNA. Also, usage of 2 reference genes, instead of 3, was recommended as 
optimum. As a result, TFCP2 and GOLGA1 were chosen as housekeeping genes to 
be used in our real-time PCR assays. 
 
 
 
 
 
 
 
Figure F4 Stability of the candidate reference genes within the normal tissue 
panel, calculated by the GeNorm software. 
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Figure F5 Determination of the optimal number of genes for normalization by 
the GeNorm software 
 
C) EQUATIONS USED FOR NORMALIZATION 
Delta Ct method 
Q = EdeltaCt  (2) 
Q = E(minCt - sampleCt)  (3) 
SD(Q) = EdeltaCt x lnE x SD(sampleCt)  (4) 
where  Q is the sample quantity relative to the reference sample 
 E is amplification efficiency (2 = 100%) 
 SD(sampleCt) is the standard deviation of the Ct values of sample replicates 
 Delta - delta Ct method 
n reference genes (REF) and one gene of interest (GOI) are to be measured and 
equations (2-4) to be applied; 
Gene of interest  GOI ± (SD GOI) 
Housekeeper 1 REF1 ± (SD REF1) 
Determination of the optimal number of control genes for normalization
0.373
0.545
0.000
0.100
0.200
0.300
0.400
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V2/3 V3/4
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Housekeeper n REFn ± (SD REFn) 
The normalization factor of n reference genes is calculated as the geometric mean: 
NFn =  REF1 × REF2 ×…  × REFn
n  (5) 
SD NFn = NFn x  
𝑆𝐷 𝑅𝐸𝐹1
𝑛×𝑅𝐸𝐹1
 
2
+  
𝑆𝐷 𝑅𝐸𝐹2
𝑛×𝑅𝐸𝐹2
 
2
+ ⋯+  
𝑆𝐷 𝑅𝐸𝐹𝑛
𝑛×𝑅𝐸𝐹𝑛
 
2
    (6) 
Normalized GOI = GOI / NF  (7) 
SD (Norm.GOI) = (Norm.GOI) x  
𝑆𝐷 𝑁𝐹𝑛
𝑁𝐹𝑛
 
2
+  
𝑆𝐷 𝐺𝑂𝐼
𝐺𝑂𝐼
 
2
   (8) 
SE = 
𝑆𝐷
 𝑚
  (9) 
where SE is the standard error 
 m is the number of measurements 
 
D) CALCULATIONS 
i) Normal Tissue Panel 
 
Table F2 Detailed calculations about the real-time PCR data for normal tissues 
          
  
Reference 
Genes 
Genes in Question 
  
TFCP2 GOLGA1 ALAS2 CDR1 GABRA3 RRAGB SLC9A6 ZCCHC12 
1 testis 
        
 
raw 23,2 23,1 33,9 17,4 25,3 21,8 21,6 26,4 
  
24,1 23,6 33,7 18 28,1 23,6 21,5 26,8 
  
23,5 23,1 31,1 18,6 25,3 23,4 24,4 26,3 
 
avg 23,60 23,27 32,90 18,00 26,23 22,93 22,50 26,50 
 
SDsample 0,46 0,29 1,56 0,60 1,62 0,99 1,65 0,26 
 
E^(deltaCt) 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 
 
SD{E^(deltaCt)} 0,318 0,200 1,083 0,416 1,121 0,684 1,141 0,183 
 
SE{E^(deltaCt)} 0,183 0,116 0,625 0,240 0,647 0,395 0,659 0,106 
 
NF 1,00000 
      
 
SE(NF) 0,10837 
      
 
Norm.GOI 
  
1,00 1,00 1,00 1,00 1,00 1,00 
 
SE(Norm.GOI) 
  
0,63 0,26 0,66 0,41 0,67 0,15 
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2 colon 
        
 
raw 23,8 26,6 34 22,2 28,2 27,4 23,1 26,5 
  
23,7 25,5 35 21,7 27,6 26,8 24,1 28 
  
24 26,6 36,6 21,8 28,2 27,4 24,6 28,7 
 
avg 23,83 26,23 35,20 21,90 28,00 27,20 23,93 27,73 
 
SDsample 0,15 0,64 1,31 0,26 0,35 0,35 0,76 1,12 
 
E^(deltaCt) 0,851 0,157 0,203 0,067 0,294 0,052 0,370 0,425 
 
SD{E^(deltaCt)} 0,090 0,069 0,185 0,012 0,071 0,012 0,196 0,331 
 
SE{E^(deltaCt)} 0,052 0,040 0,107 0,007 0,041 0,007 0,113 0,191 
 
NF 0,36562 
      
 
SE(NF) 0,13070 
      
 
Norm.GOI 
  
0,56 0,18 0,80 0,14 1,01 1,16 
 
SE(Norm.GOI) 
  
0,35 0,07 0,31 0,05 0,48 0,67 
3 spleen 
        
 
raw 30 32,8 30 25,6 28,9 28,7 32,5 28,3 
  
29,5 32,2 30,8 25,4 28,3 29,3 29,2 27,3 
  
29,5 32 30,7 25 27,8 29,8 29,5 28,1 
 
avg 29,67 32,33 30,50 25,33 28,33 29,27 30,40 27,90 
 
SDsample 0,29 0,42 0,44 0,31 0,55 0,55 1,82 0,53 
 
E^(deltaCt) 0,015 0,003 5,278 0,006 0,233 0,012 0,004 0,379 
 
SD{E^(deltaCt)} 0,003 0,001 1,595 0,001 0,089 0,005 0,005 0,139 
 
SE{E^(deltaCt)} 0,002 0,001 0,921 0,001 0,051 0,003 0,003 0,080 
 
NF 0,00722 
      
 
SE(NF) 0,10137 
      
 
Norm.GOI 
  
730,68 0,86 32,29 1,72 0,58 52,46 
 
SE(Norm.GOI) 
  
10255,09 12,05 453,24 24,10 8,14 736,28 
4 pancreas 
        
 
raw 26,3 28,3 33,4 17,2 27,5 26 24,5 28,3 
  
26,1 28,2 32 20,8 27,2 26,8 25,6 27,7 
  
26,2 28,4 32,6 17,9 27,7 26,7 25,7 27,5 
 
avg 26,20 28,30 32,67 18,63 27,47 26,50 25,27 27,83 
 
SDsample 0,10 0,10 0,70 1,91 0,25 0,44 0,67 0,42 
 
E^(deltaCt) 0,165 0,043 1,176 0,645 0,425 0,084 0,147 0,397 
 
SD{E^(deltaCt)} 0,011 0,003 0,572 0,853 0,074 0,025 0,068 0,115 
 
SE{E^(deltaCt)} 0,007 0,002 0,330 0,492 0,043 0,015 0,039 0,066 
 
NF 0,08450 
      
 
SE(NF) 0,02830 
      
 
Norm.GOI 
  
13,91 7,63 5,03 1,00 1,74 4,70 
 
SE(Norm.GOI) 
  
6,08 6,36 1,76 0,38 0,74 1,76 
5 placenta 
        
 
raw 25,9 29,1 26,2 22 27,3 25,3 26,1 27,8 
  
26,2 29,5 26,7 21,1 27,9 26,5 27,6 26,5 
  
27,6 29,7 29,9 22,2 27,4 27,1 26,4 29,2 
 
avg 26,57 29,43 26,45 21,77 27,53 26,30 26,70 27,83 
 
SDsample 0,91 0,31 2,01 0,59 0,32 0,92 0,79 1,35 
 
E^(deltaCt) 0,128 0,021 87,427 0,073 0,406 0,097 0,054 0,397 
 
SD{E^(deltaCt)} 0,080 0,005 121,653 0,030 0,090 0,062 0,030 0,371 
 
SE{E^(deltaCt)} 0,046 0,003 70,236 0,017 0,052 0,036 0,017 0,214 
 
NF 0,05226 
      
 
SE(NF) 0,19158 
      
 
Norm.GOI 
  
1672,95 1,41 7,77 1,86 1,04 7,59 
 
SE(Norm.GOI) 
  
6278,38 5,16 28,51 6,83 3,83 28,14 
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6 
small 
intestine         
 
raw 25,9 27,9 31,1 20,2 27,7 26,6 29,7 27,6 
  
25,1 27,2 30,9 20,3 28,3 26,4 23,6 27,8 
  
25,8 28,1 31,5 21 N/A 27,4 23,3 28,1 
 
avg 25,60 27,73 31,17 20,50 28,00 26,80 23,45 27,83 
 
SDsample 0,44 0,47 0,31 0,44 0,42 0,53 3,61 0,25 
 
E^(deltaCt) 0,250 0,062 3,325 0,177 0,294 0,069 0,518 0,397 
 
SD{E^(deltaCt)} 0,076 0,020 0,704 0,053 0,086 0,025 1,296 0,069 
 
SE{E^(deltaCt)} 0,044 0,012 0,407 0,031 0,050 0,015 0,748 0,040 
 
NF 0,12415 
      
 
SE(NF) 0,12864 
      
 
Norm.GOI 
  
26,78 1,42 2,37 0,55 4,17 3,20 
 
SE(Norm.GOI) 
  
27,95 1,50 2,49 0,58 7,42 3,33 
7 liver 
        
 
raw 26 27,1 32,9 21,1 29,7 26,3 24,1 28,2 
  
26,8 27,1 32,9 20,5 29 28 25,5 27,9 
  
26,3 26,9 33,7 21,3 27,6 27,6 34 28,1 
 
avg 26,37 27,03 33,17 20,97 28,77 27,30 24,80 28,07 
 
SDsample 0,40 0,12 0,46 0,42 1,07 0,89 5,36 0,15 
 
E^(deltaCt) 0,147 0,095 0,831 0,128 0,173 0,048 0,203 0,338 
 
SD{E^(deltaCt)} 0,041 0,008 0,266 0,037 0,128 0,030 0,754 0,036 
 
SE{E^(deltaCt)} 0,024 0,004 0,154 0,021 0,074 0,017 0,435 0,021 
 
NF 0,11840 
      
 
SE(NF) 0,08410 
      
 
Norm.GOI 
  
7,02 1,08 1,46 0,41 1,72 2,85 
 
SE(Norm.GOI) 
  
5,15 0,79 1,21 0,33 3,87 2,03 
8 breast 
        
 
raw 24,7 27,8 34,3 16,6 28,3 24,2 23,9 27,5 
  
25,1 27,8 34,3 15,7 28,2 26,2 24,4 28,6 
  
24,6 27,2 36,9 15,7 33,8 25,3 23,1 28,1 
 
avg 24,80 27,60 35,17 16,00 28,25 25,23 23,80 28,07 
 
SDsample 0,26 0,35 1,50 0,52 3,20 1,00 0,66 0,55 
 
E^(deltaCt) 0,435 0,067 0,208 4,000 0,247 0,203 0,406 0,338 
 
SD{E^(deltaCt)} 0,080 0,016 0,216 1,441 0,549 0,141 0,185 0,129 
 
SE{E^(deltaCt)} 0,046 0,009 0,125 0,832 0,317 0,081 0,107 0,074 
 
NF 0,17077 
      
 
SE(NF) 0,08722 
      
 
Norm.GOI 
  
1,22 23,42 1,45 1,19 2,38 1,98 
 
SE(Norm.GOI) 
  
0,96 12,92 2,00 0,77 1,37 1,10 
9 kidney 
        
 
raw 24,4 26,3 31,8 21,5 27,9 23,5 22,5 27,3 
  
24,5 26 31,7 22,2 27,9 23,9 22 27,6 
  
24,4 25,9 32,6 22,3 27,7 23,8 21,3 27,7 
 
avg 24,43 26,07 32,03 22,00 27,83 23,73 21,93 27,53 
 
SDsample 0,06 0,21 0,49 0,44 0,12 0,21 0,60 0,21 
 
E^(deltaCt) 0,561 0,174 1,823 0,063 0,330 0,574 1,481 0,489 
 
SD{E^(deltaCt)} 0,022 0,025 0,623 0,019 0,026 0,083 0,619 0,070 
 
SE{E^(deltaCt)} 0,013 0,015 0,360 0,011 0,015 0,048 0,357 0,041 
 
NF 0,31282 
      
 
SE(NF) 0,04323 
      
 
Norm.GOI 
  
5,83 0,20 1,05 1,84 4,73 1,56 
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SE(Norm.GOI) 
  
1,40 0,04 0,15 0,30 1,32 0,25 
10 prostate 
        
 
raw 26,2 27,9 30,6 19,9 28,5 25,9 26,0 28,0 
  
26,7 28,4 30,7 20,9 28,6 25,6 25,2 28,5 
  
26,1 27,8 30,5 20 27,6 25 27,1 27,4 
 
avg 26,33 28,03 30,60 20,27 28,23 25,50 26,10 27,97 
 
SDsample 0,32 0,32 0,10 0,55 0,55 0,46 0,95 0,55 
 
E^(deltaCt) 0,150 0,051 4,925 0,208 0,250 0,169 0,082 0,362 
 
SD{E^(deltaCt)} 0,034 0,011 0,341 0,079 0,095 0,054 0,055 0,138 
 
SE{E^(deltaCt)} 0,019 0,007 0,197 0,046 0,055 0,031 0,031 0,080 
 
NF 0,08768 
      
 
SE(NF) 0,09096 
      
 
Norm.GOI 
  
56,16 2,37 2,85 1,93 0,94 4,13 
 
SE(Norm.GOI) 
  
58,31 2,51 3,02 2,03 1,04 4,38 
11 bladder 
        
 
raw 25,1 26,7 29,1 18,1 29 24,6 23,8 27,8 
  
23,9 27 28,3 16,6 27,4 24,6 24,4 27,8 
  
24,3 27,3 29,4 16,7 34,2 25,3 23,7 28,2 
 
avg 24,43 27,00 28,93 17,13 28,20 24,83 23,97 27,93 
 
SDsample 0,61 0,30 0,57 0,84 3,56 0,40 0,38 0,23 
 
E^(deltaCt) 0,561 0,097 15,635 1,823 0,256 0,268 0,362 0,370 
 
SD{E^(deltaCt)} 0,238 0,020 6,162 1,060 0,630 0,075 0,095 0,059 
 
SE{E^(deltaCt)} 0,137 0,012 3,558 0,612 0,364 0,043 0,055 0,034 
 
NF 0,23381 
      
 
SE(NF) 0,13620 
      
 
Norm.GOI 
  
66,87 7,80 1,09 1,15 1,55 1,58 
 
SE(Norm.GOI) 
  
41,82 5,24 1,68 0,69 0,93 0,93 
12 ovary 
        
 
raw 24,9 27,6 33,8 18,2 27,8 24,3 21,8 26,3 
  
23,9 28,2 33,8 18,6 29,5 23,7 21,6 26,7 
  
23,8 28,5 33,6 19,6 30,1 24,1 22,4 26,8 
 
avg 24,20 28,10 33,73 18,80 29,13 24,03 21,93 26,60 
 
SDsample 0,61 0,46 0,12 0,72 1,19 0,31 0,42 0,26 
 
E^(deltaCt) 0,660 0,049 0,561 0,574 0,134 0,467 1,481 0,933 
 
SD{E^(deltaCt)} 0,278 0,016 0,045 0,287 0,111 0,099 0,427 0,171 
 
SE{E^(deltaCt)} 0,161 0,009 0,026 0,166 0,064 0,057 0,247 0,099 
 
NF 0,17988 
      
 
SE(NF) 0,15239 
      
 
Norm.GOI 
  
3,12 3,19 0,74 2,59 8,23 5,19 
 
SE(Norm.GOI) 
  
2,65 2,86 0,72 2,22 7,11 4,43 
13 brain 
        
 
raw 23,9 26,8 33,3 12,8 22,6 25,7 21 25,4 
  
23,3 27 32,5 13,9 20,1 24,2 20,6 24,7 
  
22,9 27,6 32,1 12,9 20,1 23,9 19,7 23,8 
 
avg 23,37 27,13 32,63 13,20 20,93 24,60 20,43 24,63 
 
SDsample 0,50 0,42 0,61 0,61 1,44 0,96 0,67 0,80 
 
E^(deltaCt) 1,176 0,090 1,203 27,858 39,397 0,315 4,189 3,647 
 
SD{E^(deltaCt)} 0,410 0,026 0,510 11,745 39,415 0,211 1,933 2,028 
 
SE{E^(deltaCt)} 0,237 0,015 0,294 6,781 22,756 0,122 1,116 1,171 
 
NF 0,32461 
      
 
SE(NF) 0,13070 
      
 
Norm.GOI 
  
3,71 85,82 121,37 0,97 12,91 11,23 
95 
 
 
SE(Norm.GOI) 
  
1,75 40,38 85,46 0,54 6,23 5,79 
14 esophagus 
        
 
raw 25,8 27 30,1 18,6 27,7 26,8 24,9 27,7 
  
25,6 27,6 31,5 19,6 27,9 25,4 24,1 27,7 
  
25,5 27,4 31,6 19,5 28,7 26,7 24,1 27,6 
 
avg 25,63 27,33 31,07 19,23 28,10 26,30 24,37 27,67 
 
SDsample 0,15 0,31 0,84 0,55 0,53 0,78 0,46 0,06 
 
E^(deltaCt) 0,244 0,079 3,564 0,425 0,274 0,097 0,274 0,445 
 
SD{E^(deltaCt)} 0,026 0,017 2,072 0,162 0,101 0,052 0,088 0,018 
 
SE{E^(deltaCt)} 0,015 0,010 1,196 0,094 0,058 0,030 0,051 0,010 
 
NF 0,13903 
      
 
SE(NF) 0,06835 
      
 
Norm.GOI 
  
25,63 3,06 1,97 0,70 1,97 3,20 
 
SE(Norm.GOI) 
  
15,26 1,65 1,06 0,41 1,04 1,58 
15 heart 
        
 
raw 26 27,8 30,7 18,4 28,1 27,6 24,9 28,2 
  
26,1 27,9 30,4 21,2 27,7 25,1 24,1 28,4 
  
26,6 27,5 30,2 19,4 28,7 27 23,2 28,3 
 
avg 26,23 27,73 30,43 19,67 28,17 26,57 24,07 28,30 
 
SDsample 0,32 0,21 0,25 1,42 0,50 1,31 0,85 0,10 
 
E^(deltaCt) 0,161 0,062 5,528 0,315 0,262 0,081 0,338 0,287 
 
SD{E^(deltaCt)} 0,036 0,009 0,964 0,310 0,091 0,073 0,199 0,020 
 
SE{E^(deltaCt)} 0,021 0,005 0,557 0,179 0,053 0,042 0,115 0,011 
 
NF 0,09968 
      
 
SE(NF) 0,07663 
      
 
Norm.GOI 
  
55,45 3,16 2,63 0,81 3,39 2,88 
 
SE(Norm.GOI) 
  
43,00 3,02 2,09 0,75 2,85 2,22 
16 stomach 
        
 
raw 26,8 27 34,1 21,1 28,4 26,8 25,3 27,9 
  
28 28 34,3 19,2 29,4 28,3 25,9 28,1 
  
26,2 28,2 34,8 18,9 29,3 28,2 N/A 27,6 
 
avg 27,00 27,73 34,40 19,73 29,03 27,77 25,60 27,87 
 
SDsample 0,92 0,64 0,36 1,19 0,55 0,84 0,42 0,25 
 
E^(deltaCt) 0,095 0,062 0,354 0,301 0,144 0,035 0,117 0,388 
 
SD{E^(deltaCt)} 0,060 0,027 0,088 0,249 0,055 0,020 0,034 0,068 
 
SE{E^(deltaCt)} 0,035 0,016 0,051 0,144 0,032 0,012 0,020 0,039 
 
NF 0,07642 
      
 
SE(NF) 0,22401 
      
 
Norm.GOI 
  
4,63 3,94 1,88 0,46 1,53 5,07 
 
SE(Norm.GOI) 
  
13,58 11,69 5,52 1,35 4,48 14,88 
17 lung 
        
 
raw 26,3 27,9 25 20,2 33,5 26,9 33,7 27,2 
  
26,8 28,2 25,9 19,9 27,1 27,3 25,5 28 
  
26,9 28,4 26,1 21,6 30,7 27,1 27,4 28,1 
 
avg 26,67 28,17 25,67 20,57 30,43 27,10 28,87 27,77 
 
SDsample 0,32 0,25 0,59 0,91 3,21 0,20 4,29 0,49 
 
E^(deltaCt) 0,119 0,047 150,470 0,169 0,054 0,056 0,012 0,416 
 
SD{E^(deltaCt)} 0,027 0,008 61,113 0,106 0,121 0,008 0,036 0,142 
 
SE{E^(deltaCt)} 0,015 0,005 35,284 0,061 0,070 0,004 0,021 0,082 
 
NF 0,07494 
      
 
SE(NF) 0,08169 
      
 
Norm.GOI 
  
2008,00 2,25 0,73 0,74 0,16 5,55 
 
SE(Norm.GOI) 
  
2239,02 2,59 1,22 0,81 0,33 6,14 
96 
 
 
ii) Lung Cancer Panel 
 
Table F3 Detailed calculations about the real-time PCR data for lung cancers 
 
  
Reference 
Genes 
Genes in Question 
  
TFCP2 GOLGA1 ALAS2 CDR1 RRAGB SLC9A6 
1 Normal lung       
 
raw 24,1 27,9 29 20,5 24,3 25,8 
  
26,2 29,6 29 20,8 25,4 24 
  
26,4 28 28,7 21,2 24,5 23,5 
 
avg 25,57 28,50 28,90 20,83 24,73 24,43 
 
SDsample 1,27 0,95 0,17 0,35 0,59 1,21 
 
E^(deltaCt) 1,000 1,000 1,000 1,000 1,000 1,000 
 
SD{E^(deltaCt)} 0,883 0,661 0,120 0,243 0,406 0,838 
 
SE{E^(deltaCt)} 0,510 0,382 0,069 0,141 0,234 0,484 
 
NF 1,00000 
    
 
SE(NF) 0,31848 
    
 
Norm.GOI 
  
1,00 1,00 1,00 1,00 
 
SE(Norm.GOI) 
  
0,33 0,35 0,40 0,58 
2 SK-LC-1       
 
raw 22,9 26,8 32,3 22,7 23,9 23,6 
  
23,4 27,5 31,4 25,4 24,3 24,1 
  
24,7 26,8 34 23 24,6 23,9 
 
avg 23,67 27,03 32,57 23,70 24,27 23,87 
 
SDsample 0,93 0,40 1,32 1,48 0,35 0,25 
 
E^(deltaCt) 3,732 2,497 0,079 0,137 1,382 1,481 
 
SD{E^(deltaCt)} 2,404 0,699 0,072 0,141 0,336 0,258 
 
SE{E^(deltaCt)} 1,388 0,404 0,042 0,081 0,194 0,149 
 
NF 3,05244 
    
 
SE(NF) 0,20274 
    
 
Norm.GOI 
  
0,03 0,04 0,45 0,49 
 
SE(Norm.GOI) 
  
0,01 0,03 0,07 0,06 
3 SK-LC-2       
 
raw 25,8 27,8 33,4 33,6 24,7 26,2 
  
24,6 28 33,9 32,6 24,3 26,4 
  
25,9 29,5 34,4 33 24,7 27 
 
avg 25,43 28,43 33,90 33,07 24,57 26,53 
 
SDsample 0,72 0,93 0,50 0,50 0,23 0,42 
 
E^(deltaCt) 1,097 1,042 0,031 0,000 1,122 0,233 
 
SD{E^(deltaCt)} 0,550 0,671 0,011 0,000 0,180 0,067 
 
SE{E^(deltaCt)} 0,318 0,388 0,006 0,000 0,104 0,039 
 
NF 1,06930 
    
 
SE(NF) 0,23562 
    
 
Norm.GOI 
  
0,03 0,00 1,05 0,22 
 
SE(Norm.GOI) 
  
0,01 0,00 0,25 0,06 
4 SK-LC-6       
97 
 
 
raw 26,6 29 34,7 21,1 26,7 26,6 
  
25,8 30 33 21,7 26,8 25,3 
  
25,8 29,9 33,2 21 27,6 24,9 
 
avg 26,07 29,63 33,63 21,27 27,03 25,60 
 
SDsample 0,46 0,55 0,93 0,38 0,49 0,89 
 
E^(deltaCt) 0,707 0,493 0,038 0,741 0,203 0,445 
 
SD{E^(deltaCt)} 0,226 0,188 0,024 0,194 0,069 0,274 
 
SE{E^(deltaCt)} 0,131 0,109 0,014 0,112 0,040 0,158 
 
NF 0,59051 
    
 
SE(NF) 0,14383 
    
 
Norm.GOI 
  
0,06 1,25 0,34 0,75 
 
SE(Norm.GOI) 
  
0,03 0,36 0,11 0,33 
5 SK-LC-7       
 
raw 24,1 24,9 33,7 32,2 22,6 21,3 
  
22,4 27 36,2 32,5 22,3 21,7 
  
25,2 27,3 35 31,8 21,8 22,2 
 
avg 23,90 27,15 34,97 32,17 22,23 21,73 
 
SDsample 1,41 1,31 1,25 0,35 0,40 0,45 
 
E^(deltaCt) 3,175 2,321 0,015 0,000 5,657 6,498 
 
SD{E^(deltaCt)} 3,104 2,104 0,013 0,000 1,585 2,031 
 
SE{E^(deltaCt)} 1,792 1,215 0,007 0,000 0,915 1,173 
 
NF 2,71471 
    
 
SE(NF) 0,38489 
    
 
Norm.GOI 
  
0,01 0,00 2,08 2,39 
 
SE(Norm.GOI) 
  
0,00 0,00 0,45 0,55 
6 SK-LC-8       
 
raw 23,6 25,2 34 30,7 23,4 23,3 
  
23,3 26,8 34,1 31,6 23,7 23,7 
  
24,2 27,5 34 32,5 23,9 24,3 
 
avg 23,70 26,50 34,03 31,60 23,67 23,77 
 
SDsample 0,46 1,18 0,06 0,90 0,25 0,50 
 
E^(deltaCt) 3,647 3,482 0,028 0,001 2,095 1,587 
 
SD{E^(deltaCt)} 1,158 2,845 0,001 0,000 0,365 0,554 
 
SE{E^(deltaCt)} 0,669 1,643 0,001 0,000 0,211 0,320 
 
NF 3,56347 
    
 
SE(NF) 0,25310 
    
 
Norm.GOI 
  
0,01 0,00 0,59 0,45 
 
SE(Norm.GOI) 
  
0,00 0,00 0,07 0,10 
7 SK-LC-13       
 
raw 22,6 26,4 36,3 28,4 22,2 22,6 
  
22,5 28,5 33,6 28,2 22,6 21,4 
  
22,5 27 35 29,2 23,1 22,3 
 
avg 22,53 27,30 34,97 28,60 22,63 22,10 
 
SDsample 0,06 1,08 1,35 0,53 0,45 0,62 
 
E^(deltaCt) 8,187 2,114 0,015 0,005 4,287 5,040 
 
SD{E^(deltaCt)} 0,328 1,585 0,014 0,002 1,340 2,182 
 
SE{E^(deltaCt)} 0,189 0,915 0,008 0,001 0,774 1,260 
 
NF 4,16015 
    
 
SE(NF) 0,21674 
    
 
Norm.GOI 
  
0,00 0,00 1,03 1,21 
 
SE(Norm.GOI) 
  
0,00 0,00 0,19 0,31 
8 SK-LC-14       
98 
 
 
raw 23,2 25,4 33 19,7 22,6 22 
  
23,7 26,9 36,8 20 23,3 22,3 
  
26,1 25,6 32,9 20,2 23,1 21,7 
 
avg 24,33 25,97 34,23 19,97 23,00 22,00 
 
SDsample 1,55 0,81 2,22 0,25 0,36 0,30 
 
E^(deltaCt) 2,351 4,856 0,025 1,823 3,325 5,401 
 
SD{E^(deltaCt)} 2,526 2,742 0,038 0,318 0,831 1,123 
 
SE{E^(deltaCt)} 1,459 1,583 0,022 0,184 0,480 0,648 
 
NF 3,37901 
    
 
SE(NF) 0,35040 
    
 
Norm.GOI 
  
0,01 0,54 0,98 1,60 
 
SE(Norm.GOI) 
  
0,01 0,08 0,17 0,25 
9 SK-LC-17       
 
raw 22,1 24,7 35,6 29,8 24,0 24,1 
  
23,1 27,7 34 29,2 24 24,1 
  
22,4 26,6 33,5 29,8 24,2 24,6 
 
avg 22,53 26,33 34,37 29,60 24,07 24,27 
 
SDsample 0,51 1,52 1,10 0,35 0,12 0,29 
 
E^(deltaCt) 8,187 3,863 0,023 0,002 1,587 1,122 
 
SD{E^(deltaCt)} 2,912 4,064 0,017 0,001 0,127 0,225 
 
SE{E^(deltaCt)} 1,681 2,346 0,010 0,000 0,073 0,130 
 
NF 5,62406 
    
 
SE(NF) 0,32057 
    
 
Norm.GOI 
  
0,00 0,00 0,28 0,20 
 
SE(Norm.GOI) 
  
0,00 0,00 0,02 0,03 
10 NCI-H69       
 
raw 21,7 27,8 35,4 20,5 23,1 24,0 
  
21,7 28,4 34,7 20,8 22,9 24,2 
  
22,4 28,4 33 21,1 23,6 23,7 
 
avg 21,93 28,20 34,37 20,80 23,20 23,97 
 
SDsample 0,40 0,35 1,23 0,30 0,36 0,25 
 
E^(deltaCt) 12,409 1,206 0,023 1,023 2,895 1,382 
 
SD{E^(deltaCt)} 3,476 0,290 0,019 0,213 0,723 0,241 
 
SE{E^(deltaCt)} 2,007 0,167 0,011 0,123 0,418 0,139 
 
NF 3,86819 
    
 
SE(NF) 0,10651 
    
 
Norm.GOI 
  
0,01 0,26 0,75 0,36 
 
SE(Norm.GOI) 
  
0,00 0,03 0,11 0,04 
11 NCI-H82       
 
raw 22,6 26,5 32,8 34,8 25,5 22,1 
  
23,6 28,5 34 33 25,8 22,7 
  
22,3 28,4 32,9 33,3 25,1 22,5 
 
avg 22,83 27,80 33,23 33,70 25,47 22,43 
 
SDsample 0,68 1,13 0,67 0,96 0,35 0,31 
 
E^(deltaCt) 6,650 1,548 0,050 0,000 0,602 4,000 
 
SD{E^(deltaCt)} 3,138 1,209 0,023 0,000 0,146 0,847 
 
SE{E^(deltaCt)} 1,811 0,698 0,013 0,000 0,085 0,489 
 
NF 3,20794 
    
 
SE(NF) 0,26344 
    
 
Norm.GOI 
  
0,02 0,00 0,19 1,25 
 
SE(Norm.GOI) 
  
0,00 0,00 0,03 0,18 
12 NCI-H128       
99 
 
 
raw 22 26,3 33,2 32,7 24,7 23,3 
  
21,9 26,4 35 32,1 22,9 22,5 
  
22,2 27,5 35,5 34,4 23,4 24,3 
 
avg 22,03 26,73 34,57 33,07 23,67 23,37 
 
SDsample 0,15 0,67 1,21 1,19 0,93 0,90 
 
E^(deltaCt) 11,578 3,010 0,020 0,000 2,095 2,095 
 
SD{E^(deltaCt)} 1,226 1,389 0,017 0,000 1,349 1,309 
 
SE{E^(deltaCt)} 0,708 0,802 0,010 0,000 0,779 0,756 
 
NF 5,90371 
    
 
SE(NF) 0,13669 
    
 
Norm.GOI 
  
0,00 0,00 0,35 0,35 
 
SE(Norm.GOI) 
  
0,00 0,00 0,13 0,13 
13 NCI-H146       
 
raw 23,3 28,5 33,3 35,7 25,5 22,8 
  
24,2 28,2 33,7 36,4 23,2 23 
  
22,6 28,5 32,3 33,6 23 24,9 
 
avg 23,37 28,40 33,10 35,23 23,90 23,57 
 
SDsample 0,80 0,17 0,72 1,46 1,39 1,16 
 
E^(deltaCt) 4,595 1,064 0,054 0,000 1,782 1,823 
 
SD{E^(deltaCt)} 2,555 0,128 0,027 0,000 1,716 1,465 
 
SE{E^(deltaCt)} 1,475 0,074 0,016 0,000 0,991 0,846 
 
NF 2,21146 
    
 
SE(NF) 0,16419 
    
 
Norm.GOI 
  
0,02 0,00 0,81 0,82 
 
SE(Norm.GOI) 
  
0,01 0,00 0,45 0,39 
14 NCI-H209       
 
raw 23,8 27 35,7 29,5 24,1 23,6 
  
24 26,9 36,1 28,8 25,5 23,4 
  
23,6 25,7 34 28,9 24,2 23,1 
 
avg 23,80 26,53 35,27 29,07 24,60 23,37 
 
SDsample 0,20 0,72 1,12 0,38 0,78 0,25 
 
E^(deltaCt) 3,403 3,410 0,012 0,003 1,097 2,095 
 
SD{E^(deltaCt)} 0,472 1,710 0,009 0,001 0,594 0,365 
 
SE{E^(deltaCt)} 0,272 0,987 0,005 0,001 0,343 0,211 
 
NF 3,40648 
    
 
SE(NF) 0,15018 
    
 
Norm.GOI 
  
0,00 0,00 0,32 0,61 
 
SE(Norm.GOI) 
  
0,00 0,00 0,10 0,07 
15 NCI-H345       
 
raw 24,8 28 33,5 22,7 21,5 21,6 
  
25 27,3 36,3 23,1 22,1 21,6 
  
25,3 29,1 34,3 23,4 21,9 22 
 
avg 25,03 28,13 34,70 23,07 21,83 21,73 
 
SDsample 0,25 0,91 1,44 0,35 0,31 0,23 
 
E^(deltaCt) 1,447 1,257 0,018 0,213 7,464 6,498 
 
SD{E^(deltaCt)} 0,252 0,791 0,018 0,052 1,581 1,040 
 
SE{E^(deltaCt)} 0,146 0,456 0,010 0,030 0,913 0,601 
 
NF 1,34878 
    
 
SE(NF) 0,18841 
    
 
Norm.GOI 
  
0,01 0,16 5,53 4,82 
 
SE(Norm.GOI) 
  
0,01 0,03 1,03 0,81 
16 NCI-H378       
100 
 
 
raw 25,5 28 34,5 19,3 23,6 23,5 
  
24,3 28,9 35,9 20,6 24,3 23,4 
  
26,9 29 31,9 19,3 27,1 24,2 
 
avg 25,57 28,63 34,10 19,73 25,00 23,70 
 
SDsample 1,30 0,55 2,03 0,75 1,85 0,44 
 
E^(deltaCt) 1,000 0,920 0,027 2,144 0,831 1,662 
 
SD{E^(deltaCt)} 0,902 0,351 0,038 1,115 1,067 0,502 
 
SE{E^(deltaCt)} 0,521 0,203 0,022 0,644 0,616 0,290 
 
NF 0,95927 
    
 
SE(NF) 0,28274 
    
 
Norm.GOI 
  
0,03 2,23 0,87 1,73 
 
SE(Norm.GOI) 
  
0,02 0,94 0,69 0,59 
17 KNS62       
 
raw 23,9 27,5 33,3 30,5 24,1 23,3 
  
23,7 28,4 32,9 30,7 23,8 25,1 
  
23,9 25,9 33,4 31,4 24,6 26,8 
 
avg 23,83 27,27 33,20 30,87 24,17 25,07 
 
SDsample 0,12 1,27 0,26 0,47 0,40 1,75 
 
E^(deltaCt) 3,325 2,158 0,051 0,001 1,481 0,645 
 
SD{E^(deltaCt)} 0,266 1,894 0,009 0,000 0,415 0,782 
 
SE{E^(deltaCt)} 0,154 1,094 0,005 0,000 0,240 0,452 
 
NF 2,67889 
    
 
SE(NF) 0,25442 
    
 
Norm.GOI 
  
0,02 0,00 0,55 0,24 
 
SE(Norm.GOI) 
  
0,00 0,00 0,10 0,17 
18 NCI-H889       
 
raw 21,8 27,7 34,1 33,6 23,4 22,1 
  
22,3 28,5 33,7 33 24,5 22,2 
  
22,2 28,2 36,2 31,7 23,7 22 
 
avg 22,10 28,13 34,67 32,77 23,87 22,10 
 
SDsample 0,26 0,40 1,34 0,97 0,57 0,10 
 
E^(deltaCt) 11,055 1,257 0,018 0,000 1,823 5,040 
 
SD{E^(deltaCt)} 2,027 0,352 0,017 0,000 0,719 0,349 
 
SE{E^(deltaCt)} 1,171 0,203 0,010 0,000 0,415 0,202 
 
NF 3,72780 
    
 
SE(NF) 0,09665 
    
 
Norm.GOI 
  
0,00 0,00 0,49 1,35 
 
SE(Norm.GOI) 
  
0,00 0,00 0,11 0,06 
19 Calu1       
 
raw 25,2 28 32,2 28,1 24,9 25,5 
  
25,4 27,5 32,6 28 24,8 24,8 
  
25,8 27,9 31,1 28,4 25,5 25,7 
 
avg 25,47 27,80 31,97 28,17 25,07 25,33 
 
SDsample 0,31 0,26 0,78 0,21 0,38 0,47 
 
E^(deltaCt) 1,072 1,548 0,119 0,006 0,794 0,536 
 
SD{E^(deltaCt)} 0,227 0,284 0,064 0,001 0,208 0,176 
 
SE{E^(deltaCt)} 0,131 0,164 0,037 0,001 0,120 0,101 
 
NF 1,28787 
    
 
SE(NF) 0,08087 
    
 
Norm.GOI 
  
0,09 0,00 0,62 0,42 
 
SE(Norm.GOI) 
  
0,03 0,00 0,10 0,08 
20 Calu3       
101 
 
 
raw 26 28,4 30,9 35,6 25,2 23,9 
  
26,3 28,6 30,7 34,9 25 23,1 
 
 26,8 28 31,1 34 24,9 23,9 
 
avg 26,37 28,33 30,90 34,83 25,03 23,63 
 
SDsample 0,40 0,31 0,20 0,80 0,15 0,46 
 
E^(deltaCt) 0,574 1,110 0,250 0,000 0,812 1,741 
 
SD{E^(deltaCt)} 0,161 0,235 0,035 0,000 0,086 0,557 
 
SE{E^(deltaCt)} 0,093 0,136 0,020 0,000 0,050 0,322 
 
NF 0,79830 
    
 
SE(NF) 0,10137 
    
 
Norm.GOI 
  
0,31 0,00 1,02 2,18 
 
SE(Norm.GOI) 
  
0,05 0,00 0,14 0,49 
 
 
iii) Colon Cancer Panel 
 
Table F4 Detailed calculations about the real-time PCR data for colon cancers 
 
  
Reference 
Genes 
Genes in Question 
  
TFCP2 GOLGA1 CDR1 GABRA3 RRAGB SLC9A6 ZCCHC12 
1 Normal colon 
       
 
raw 26,8 24,10 21,4 30,9 22,9 23,2 30,5 
  
24,4 24,50 22,6 30,8 23 23 30,3 
  
21,9 25,90 21,1 32,1 23,3 23,4 29,4 
 
avg 24,37 24,83 21,70 31,27 23,07 23,20 30,07 
 
SDsample 2,45 0,95 0,79 0,72 0,21 0,20 0,59 
 
E^(deltaCt) 1,000 1,000 1,000 1,000 1,000 1,000 1,000 
 
SD{E^(deltaCt)} 1,698 0,655 0,550 0,501 0,144 0,139 0,406 
 
SE{E^(deltaCt)} 0,981 0,378 0,318 0,290 0,083 0,080 0,234 
 
NF 1,00000 
     
 
SE(NF) 0,52548 
     
 
Norm.GOI 
  
1,00 1,00 1,00 1,00 1,00 
 
SE(Norm.GOI) 
  
0,61 0,60 0,53 0,53 0,58 
2 SW403 
       
 
raw 22,3 25,70 27,7 22,6 24,7 22,3 33,6 
  
23,3 28,80 27,4 24,6 26,4 23,1 34,7 
  
23,8 27,30 28,5 24,2 26,3 23,6 34,1 
 
avg 23,13 27,27 27,87 23,80 25,80 23,00 34,13 
 
SDsample 0,76 1,55 0,57 1,06 0,95 0,66 0,55 
 
E^(deltaCt) 2,351 0,219 0,014 176,885 0,150 1,149 0,060 
 
SD{E^(deltaCt)} 1,245 0,236 0,005 129,755 0,099 0,522 0,023 
 
SE{E^(deltaCt)} 0,719 0,136 0,003 74,914 0,057 0,301 0,013 
 
NF 0,71784 
     
 
SE(NF) 0,34580 
     
 
Norm.GOI 
  
0,02 246,41 0,21 1,60 0,08 
 
SE(Norm.GOI) 
  
0,01 158,06 0,13 0,88 0,04 
3 SW480 
       
102 
 
 
raw 23,5 27,80 29 28,6 23,6 22,3 28,7 
  
25,2 28,50 29,1 29 26,4 23,2 28,7 
  
25,2 28,20 30,6 29,3 24,7 23,5 31,4 
 
avg 24,63 28,17 29,57 28,97 24,90 23,00 29,60 
 
SDsample 0,98 0,35 0,90 0,35 1,41 0,62 1,56 
 
E^(deltaCt) 0,831 0,125 0,004 4,925 0,281 1,149 1,382 
 
SD{E^(deltaCt)} 0,566 0,030 0,003 1,199 0,274 0,497 1,493 
 
SE{E^(deltaCt)} 0,326 0,018 0,002 0,692 0,158 0,287 0,862 
 
NF 0,32236 
     
 
SE(NF) 0,20858 
     
 
Norm.GOI 
  
0,01 15,28 0,87 3,56 4,29 
 
SE(Norm.GOI) 
  
0,01 10,12 0,75 2,47 3,85 
4 SW620 
       
 
raw 26,9 29,60 29,7 29,8 28 27,2 37,4 
  
27,6 29,90 31,8 32,1 30,4 25 33,7 
  
25,7 28,20 32,6 29,4 26 26,2 33,5 
 
avg 26,73 29,23 31,37 30,43 28,13 26,13 34,87 
 
SDsample 0,96 0,91 1,50 1,46 2,20 1,10 2,20 
 
E^(deltaCt) 0,194 0,064 0,001 1,782 0,030 0,131 0,036 
 
SD{E^(deltaCt)} 0,129 0,040 0,001 1,800 0,046 0,100 0,055 
 
SE{E^(deltaCt)} 0,075 0,023 0,001 1,039 0,026 0,058 0,032 
 
NF 0,11163 
     
 
SE(NF) 0,26445 
     
 
Norm.GOI 
  
0,01 15,96 0,27 1,17 0,32 
 
SE(Norm.GOI) 
  
0,03 38,94 0,68 2,83 0,81 
5 SW837 
       
 
raw 22,7 26,50 30,8 22,8 24,8 21,4 28,9 
  
23,3 25,20 30,5 23,2 24 21,8 28,6 
  
21,7 24,80 30,7 23,3 25,9 22 28,9 
 
avg 22,57 25,50 30,67 23,10 24,90 21,73 28,80 
 
SDsample 0,81 0,89 0,15 0,26 0,95 0,31 0,17 
 
E^(deltaCt) 3,482 0,660 0,002 287,350 0,281 2,764 2,406 
 
SD{E^(deltaCt)} 1,951 0,406 0,000 52,697 0,186 0,585 0,289 
 
SE{E^(deltaCt)} 1,126 0,235 0,000 30,425 0,107 0,338 0,167 
 
NF 1,51573 
     
 
SE(NF) 0,24039 
     
 
Norm.GOI 
  
0,00 189,58 0,19 1,82 1,59 
 
SE(Norm.GOI) 
  
0,00 36,15 0,08 0,37 0,27 
6 SW1222 
       
 
raw 25,3 27,60 33 33,1 24,8 22,3 33,5 
  
25,2 27,50 30,6 32,1 24,2 23,1 32,9 
  
24,6 26,70 31,6 33,1 24,5 23 33,7 
 
avg 25,03 27,27 31,73 32,77 24,50 22,80 33,37 
 
SDsample 0,38 0,49 1,21 0,58 0,30 0,44 0,42 
 
E^(deltaCt) 0,630 0,219 0,001 0,354 0,370 1,320 0,102 
 
SD{E^(deltaCt)} 0,165 0,075 0,001 0,141 0,077 0,399 0,029 
 
SE{E^(deltaCt)} 0,095 0,043 0,000 0,082 0,044 0,230 0,017 
 
NF 0,37158 
     
 
SE(NF) 0,12442 
     
 
Norm.GOI 
  
0,00 0,95 1,00 3,55 0,27 
 
SE(Norm.GOI) 
  
0,00 0,39 0,35 1,34 0,10 
7 HCT15 
       
 
raw 22,8 25,50 26,2 25,2 23,7 20,6 29 
103 
 
  
23,2 23,90 27,3 26,1 22,5 21,1 28,2 
  
25,3 26,80 27,7 26,4 23,5 21,5 29,1 
 
avg 23,77 25,40 27,07 25,90 23,23 21,07 28,77 
 
SDsample 1,34 1,45 0,78 0,62 0,64 0,45 0,49 
 
E^(deltaCt) 1,516 0,702 0,024 41,260 0,891 4,387 2,462 
 
SD{E^(deltaCt)} 1,411 0,707 0,013 17,860 0,397 1,371 0,842 
 
SE{E^(deltaCt)} 0,815 0,408 0,008 10,312 0,229 0,792 0,486 
 
NF 1,03169 
     
 
SE(NF) 0,39583 
     
 
Norm.GOI 
  
0,02 39,99 0,86 4,25 2,39 
 
SE(Norm.GOI) 
  
0,01 18,31 0,40 1,80 1,03 
8 HCT116 
       
 
raw 24,8 29,40 30,3 37,2 24,3 22,9 29,2 
  
25,3 27,60 31,3 37,2 24,8 23 30,4 
  
24,4 27,40 30,8 37,2 24,5 23,1 29,3 
 
avg 24,83 28,13 30,80 37,20 24,53 23,00 29,63 
 
SDsample 0,45 1,10 0,50 0,00 0,25 0,10 0,67 
 
E^(deltaCt) 0,724 0,128 0,002 0,016 0,362 1,149 1,350 
 
SD{E^(deltaCt)} 0,226 0,097 0,001 0,000 0,063 0,080 0,623 
 
SE{E^(deltaCt)} 0,131 0,056 0,000 0,000 0,036 0,046 0,360 
 
NF 0,30392 
     
 
SE(NF) 0,23816 
     
 
Norm.GOI 
  
0,01 0,05 1,19 3,78 4,44 
 
SE(Norm.GOI) 
  
0,00 0,04 0,94 2,97 3,68 
9 SK-CO-10 
       
 
raw 22,9 27,60 27,9 23,2 24,8 20,7 32,7 
  
22,4 27,90 28,7 23,8 25,8 21,9 33,7 
  
22,5 25,20 31 22,3 26,4 20,7 31,3 
 
avg 22,60 26,90 29,20 23,10 25,67 21,10 32,57 
 
SDsample 0,26 1,48 1,61 0,75 0,81 0,69 1,21 
 
E^(deltaCt) 3,403 0,275 0,006 287,350 0,165 4,287 0,177 
 
SD{E^(deltaCt)} 0,624 0,283 0,006 150,375 0,092 2,059 0,148 
 
SE{E^(deltaCt)} 0,360 0,163 0,004 86,819 0,053 1,189 0,085 
 
NF 0,96821 
     
 
SE(NF) 0,30081 
     
 
Norm.GOI 
  
0,01 296,79 0,17 4,43 0,18 
 
SE(Norm.GOI) 
  
0,00 128,62 0,08 1,84 0,10 
10 SK-CO-17 
       
 
raw 22,9 25,00 31,0 25,7 27,2 23,2 32,5 
  
23,4 26,50 29,3 26,6 25,4 22,9 31,1 
  
24,5 28,00 33,2 23,9 25,6 23,7 33,3 
 
avg 23,60 26,50 31,17 25,40 26,07 23,27 32,30 
 
SDsample 0,82 1,50 1,96 1,37 0,99 0,40 1,11 
 
E^(deltaCt) 1,701 0,354 0,001 58,350 0,125 0,955 0,213 
 
SD{E^(deltaCt)} 0,965 0,368 0,002 55,603 0,085 0,267 0,164 
 
SE{E^(deltaCt)} 0,557 0,212 0,001 32,102 0,049 0,154 0,095 
 
NF 0,77560 
     
 
SE(NF) 0,34192 
     
 
Norm.GOI 
  
0,00 75,23 0,16 1,23 0,27 
 
SE(Norm.GOI) 
  
0,00 53,04 0,10 0,58 0,17 
11 SK-CO-19 
       
 
raw 23,2 27,90 31,8 26 24,3 24,3 29,8 
  
24,3 28,60 33,9 25,8 25 23,4 30,8 
104 
 
  
23,9 27,90 34 27,4 24,7 24,1 29,8 
 
avg 23,80 28,13 33,23 26,40 24,67 23,93 30,13 
 
SDsample 0,56 0,40 1,24 0,87 0,35 0,47 0,58 
 
E^(deltaCt) 1,481 0,128 0,000 29,175 0,330 0,602 0,955 
 
SD{E^(deltaCt)} 0,572 0,036 0,000 17,630 0,080 0,197 0,382 
 
SE{E^(deltaCt)} 0,330 0,021 0,000 10,179 0,046 0,114 0,221 
 
NF 0,43480 
     
 
SE(NF) 0,13766 
     
 
Norm.GOI 
  
0,00 67,10 0,76 1,38 2,20 
 
SE(Norm.GOI) 
  
0,00 31,61 0,26 0,51 0,86 
12 CaCO2 
       
 
raw 21,7 24,10 32,8 37 22,9 22,3 32,1 
  
21,9 24,20 31,6 35,9 22,8 21,5 32,1 
  
22,1 24,10 30,5 36 23,7 22,6 33,4 
 
avg 21,90 24,13 31,63 36,30 23,13 22,13 32,53 
 
SDsample 0,20 0,06 1,15 0,61 0,49 0,57 0,75 
 
E^(deltaCt) 5,528 1,548 0,001 0,031 0,955 2,095 0,181 
 
SD{E^(deltaCt)} 0,766 0,062 0,001 0,013 0,326 0,826 0,094 
 
SE{E^(deltaCt)} 0,442 0,036 0,000 0,007 0,188 0,477 0,054 
 
NF 2,92475 
     
 
SE(NF) 0,04165 
     
 
Norm.GOI 
  
0,00 0,01 0,33 0,72 0,06 
 
SE(Norm.GOI) 
  
0,00 0,00 0,06 0,16 0,02 
13 Colo205 
       
 
raw 24 23,60 31 28,7 25 23,2 36,7 
  
24,9 26,80 29 29,3 25,5 23,4 38,3 
  
27 25,30 32,2 30,6 25,4 23,3 35,4 
 
avg 25,30 25,23 30,73 29,53 25,30 23,30 36,80 
 
SDsample 1,54 1,60 1,62 0,97 0,26 0,10 1,45 
 
E^(deltaCt) 0,524 0,779 0,002 3,325 0,213 0,933 0,009 
 
SD{E^(deltaCt)} 0,559 0,865 0,002 2,238 0,039 0,065 0,009 
 
SE{E^(deltaCt)} 0,323 0,499 0,001 1,292 0,023 0,037 0,005 
 
NF 0,63876 
     
 
SE(NF) 0,44443 
     
 
Norm.GOI 
  
0,00 5,21 0,33 1,46 0,01 
 
SE(Norm.GOI) 
  
0,00 4,15 0,23 1,02 0,01 
14 Lim1215 
       
 
raw 23,4 25,80 33,1 36,9 24,5 23 34,5 
  
25,8 26,40 32,9 37,3 25,6 21,9 33,1 
  
23 27,10 31,9 37 24,7 22,2 32,9 
 
avg 24,07 26,43 32,63 37,07 24,93 22,37 33,50 
 
SDsample 1,51 0,65 0,64 0,21 0,59 0,57 0,87 
 
E^(deltaCt) 1,231 0,369 0,001 0,018 0,274 1,782 0,093 
 
SD{E^(deltaCt)} 1,292 0,166 0,000 0,003 0,111 0,702 0,056 
 
SE{E^(deltaCt)} 0,746 0,096 0,000 0,001 0,064 0,405 0,032 
 
NF 0,67364 
     
 
SE(NF) 0,32980 
     
 
Norm.GOI 
  
0,00 0,03 0,41 2,65 0,14 
 
SE(Norm.GOI) 
  
0,00 0,01 0,22 1,43 0,08 
15 Ls180 
       
 
raw 23,2 25,10 28,9 27,2 24 20,9 33,6 
  
23,7 24,60 28,8 29,4 25,1 22,8 33,2 
  
23,5 25,60 29 27,4 26,1 23,1 33,6 
105 
 
 
avg 23,47 25,10 28,90 28,00 25,07 22,27 33,47 
 
SDsample 0,25 0,50 0,10 1,22 1,05 1,19 0,23 
 
E^(deltaCt) 1,866 0,847 0,007 9,624 0,250 1,910 0,095 
 
SD{E^(deltaCt)} 0,326 0,293 0,000 8,116 0,182 1,579 0,015 
 
SE{E^(deltaCt)} 0,188 0,169 0,000 4,686 0,105 0,912 0,009 
 
NF 1,25702 
     
 
SE(NF) 0,11201 
     
 
Norm.GOI 
  
0,01 7,66 0,20 1,52 0,08 
 
SE(Norm.GOI) 
  
0,00 3,79 0,09 0,74 0,01 
16 Ls174-T 
       
 
raw 29,3 28,50 30,3 28 26,7 27,2 34,9 
  
29,5 28,40 31,4 30,2 25,9 31 36,5 
  
29,6 30,00 29,9 29,6 26,1 30,9 33,7 
 
avg 29,47 28,97 30,53 29,27 26,23 29,70 35,03 
 
SDsample 0,15 0,90 0,78 1,14 0,42 2,17 1,40 
 
E^(deltaCt) 0,029 0,076 0,002 4,000 0,111 0,011 0,032 
 
SD{E^(deltaCt)} 0,003 0,047 0,001 3,153 0,032 0,017 0,031 
 
SE{E^(deltaCt)} 0,002 0,027 0,001 1,820 0,019 0,010 0,018 
 
NF 0,04704 
     
 
SE(NF) 0,18193 
     
 
Norm.GOI 
  
0,05 85,03 2,37 0,23 0,68 
 
SE(Norm.GOI) 
  
0,18 331,11 9,16 0,93 2,66 
17 LoVo 
       
 
raw 22,6 26,90 34,2 34,2 26,3 22,5 35,1 
  
23,1 24,60 32,6 32,2 25,9 22,7 32,8 
  
21,9 25,00 34,1 33,1 25 22,7 34,2 
 
avg 22,53 25,50 33,63 33,17 25,73 22,63 34,03 
 
SDsample 0,60 1,23 0,90 1,00 0,67 0,12 1,16 
 
E^(deltaCt) 3,564 0,660 0,000 0,268 0,157 1,481 0,064 
 
SD{E^(deltaCt)} 1,489 0,562 0,000 0,186 0,073 0,119 0,051 
 
SE{E^(deltaCt)} 0,860 0,324 0,000 0,107 0,042 0,068 0,030 
 
NF 1,53335 
     
 
SE(NF) 0,27387 
     
 
Norm.GOI 
  
0,00 0,17 0,10 0,97 0,04 
 
SE(Norm.GOI) 
  
0,00 0,08 0,03 0,18 0,02 
18 DLD-1 
       
 
raw 24,7 25,10 26,4 28,7 22,8 21 29,8 
  
25,7 25,20 29,3 31 23,6 21,5 29,2 
  
25,1 26,40 28,9 29,5 23,9 21,3 31,7 
 
avg 25,17 25,57 28,20 29,73 23,43 21,27 30,23 
 
SDsample 0,50 0,72 1,57 1,17 0,57 0,25 1,31 
 
E^(deltaCt) 0,574 0,633 0,011 2,895 0,776 3,819 0,891 
 
SD{E^(deltaCt)} 0,200 0,317 0,012 2,343 0,306 0,666 0,806 
 
SE{E^(deltaCt)} 0,116 0,183 0,007 1,353 0,176 0,385 0,465 
 
NF 0,60291 
     
 
SE(NF) 0,17634 
     
 
Norm.GOI 
  
0,02 4,80 1,29 6,33 1,48 
 
SE(Norm.GOI) 
  
0,01 2,65 0,48 1,96 0,88 
19 Snu-C2B 
       
 
raw 25,3 29,10 30,8 29,7 23,8 21,4 33,2 
  
25,9 29,10 29,1 33,7 23,7 22,1 33,3 
  
24,8 28,80 31,3 31,2 26,1 23,2 34,6 
 
avg 25,33 29,00 30,40 31,53 24,53 22,23 33,70 
106 
 
 
SDsample 0,55 0,17 1,15 2,02 1,36 0,91 0,78 
 
E^(deltaCt) 0,512 0,074 0,002 0,831 0,362 1,954 0,081 
 
SD{E^(deltaCt)} 0,195 0,009 0,002 1,164 0,340 1,229 0,044 
 
SE{E^(deltaCt)} 0,113 0,005 0,001 0,672 0,197 0,710 0,025 
 
NF 0,19503 
     
 
SE(NF) 0,11552 
     
 
Norm.GOI 
  
0,01 4,26 1,86 10,02 0,41 
 
SE(Norm.GOI) 
  
0,01 4,27 1,49 6,96 0,28 
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APPENDIX F: SEQUENCING RESULTS OF THE 3C ASSAY 
 
Figures presented below show the identity of alignments between the sequencing 
results and expected sequence when DNA is digested from indicated restriction 
sites (yellow in the sequence alignment) and ligated by T4 DNA ligase. Details of 
alignments are also shown below the figures. The gaps at the beginning of the 
alignments are due to imperfections in the sequencing experiments for the first 20 
to 25 bases. 
 
Primers 2-10 
 
 
 
 
 
Score =  274 bits (138), Expect = 9e-79 
Identities = 138/138 (100%) 
Strand = Plus / Plus 
 
                                                                        
Query: 26 gggaatgaggccccagaggacagatgagcatcatgggcagagcggggtcagattccccgt 85 
          |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct: 55 gggaatgaggccccagaggacagatgagcatcatgggcagagcggggtcagattccccgt 114 
 
                                                                        
Query: 86 gaattcgagtcacttacaaacaaagtggcataaggccaggcacagtggcccatgcctata 145 
          |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct: 115gaattcgagtcacttacaaacaaagtggcataaggccaggcacagtggcccatgcctata 174 
 
                              
Query: 146 atcccagcactttcggag 163 
           |||||||||||||||||| 
Sbjct: 175 atcccagcactttcggag 192 
 
Primers 4-12 
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Score =  242 bits (122), Expect = 3e-69 
Identities = 122/122 (100%) 
Strand = Plus / Plus 
 
                                                                        
Query: 23 agtggactcttcagacttgacttggaattctcttgtacgttgtagggtgtggagcagagt 82 
          |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct: 53 agtggactcttcagacttgacttggaattctcttgtacgttgtagggtgtggagcagagt 112 
 
                                                                        
Query: 83 ccctggcctgtacctgctagatgccagtagcacctgtcctgttgtgacaactaacaatat 142 
          |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct: 113ccctggcctgtacctgctagatgccagtagcacctgtcctgttgtgacaactaacaatat 172 
 
              
Query: 143 cc 144 
           || 
Sbjct: 173 cc 174 
 
 
Primers 6-8 
 
 
 
 
 
Score =  236 bits (119), Expect = 2e-67 
Identities = 126/127 (99%), Gaps = 1/127 (0%) 
Strand = Plus / Plus 
 
                                                                        
Query: 20 catgggaggg-cctggtgggaggtaactgaatcatgggggcggatgtttcccgtgctgtt 78 
          |||||||||| ||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct: 47 catgggagggacctggtgggaggtaactgaatcatgggggcggatgtttcccgtgctgtt 106 
 
                                                                        
Query: 79 ctcgtgatagtgaataagtctcatgagatctgtattttgaacaatgatgcctgttggaga 138 
          |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct: 107ctcgtgatagtgaataagtctcatgagatctgtattttgaacaatgatgcctgttggaga 166 
 
                   
Query: 139 atgtgca 145 
           ||||||| 
Sbjct: 167 atgtgca 173 
 
